

## SETTLEMENT AGREEMENT

This Settlement Agreement dated as of February 16, 2007 ("Agreement") by and among the United States of America, acting by and through the United States' Department of Health and Human Services, National Institutes of Health ("NIH"), Therion Biologics Corporation, a Delaware corporation with its principal place of business at 76 Rogers Street, Cambridge, MA 02142-1119 ("Therion"), and Kranich Vermögens-und Beteiligungsverwaltungs GmbH, a German entity, c/o Eagle Advisors, Inc., Three World Financial Center, 200 Vesey Street, 25<sup>th</sup> Floor, New York, NY 10281 ("Kranich") (individually, a "Party" and collectively, "Parties").

### DEFINITIONS

The following definitions shall be applicable to this Agreement unless otherwise specified:

"**NCI**" means the National Cancer Institute, a governmental organization within NIH.

"**CRADA**" mean the Cooperative Research and Development Agreement, Number 00220, between Therion and the NCI through the laboratory of Dr. Jeffrey Schlom, dated September 26, 1994, as amended through 2006. The term "CRADA" as used in this Agreement refers to the CRADA between Therion and Dr. Schlom of the NCI.

"**Agent(s)**" means Therion's investigational recombinant poxviral vectors incorporating the Laboratory of Tumor Immunology and Biology ("LTIB") at NIH's proprietary antigens and/or co-stimulatory factors and/or other genes or materials which were provided by Therion.

"**Research Plan**" means the statement of the respected research and development commitments of NIH and Therion pursuant to the CRADA from and after the execution date of the original CRADA (September 26, 1994).

"**Research Materials**" means all tangible materials other than Subject Data first produced in the performance of the CRADA.

"**FDA**" means the Food and Drug Administration.

"**IND**" means an Investigational New Drug Application submitted to the FDA to receive approval to conduct experimental clinical trials.

"**Clinical Data and Results**" means all information, data and results developed or obtained in connection with clinical trials conducted within the scope of the CRADA Research Plan whether by intramural research scientists or extramural grantee or contract investigators.

"**Raw Data**" means the primary quantitative and empirical data first collected by the intramural and extramural investigators from experiments and clinical trials conducted within the scope of

the Research Plan of the CRADA.

**“Summary Data”** means a summary of the Raw Data provided to NIH by the extramural investigators that was either included by NIH in an annual report to an NIH-sponsored IND, or made available by NIH to Therion for submission to the FDA under a Therion sponsored IND.

**“Subject Data”** means all recorded information first produced in the performance of the CRADA.

**“Proprietary/Confidential Information”** means confidential scientific, business or financial information or proprietary materials, provided that such information or materials do not include: (1) information or materials that are publicly known or available from other sources who are not under a confidentiality obligation to the source of the information or materials; (2) information or materials which have been made available by its owners to others without a confidentiality obligation; (3) information or materials which are already known by or available to the receiving party without a confidentiality obligation; or (4) information which relates to potential hazards or cautionary warnings associated with the production, handling or the use of the subject matter of the Research Plan of the CRADA.

**“Subject Invention”** means any invention of the Parties, conceived or first actually reduced to practice in the performance of research under the CRADA.

**“Invention”** means any invention or discovery which is or may be patentable or otherwise protected under title 35, United States Code, or any novel variety or plant which is or may be protectable under the Plant Variety Protection Act (7 U.S.C. § 2321 et seq.)

**“Co-Owned Inventions”** means Inventions owned jointly by at least Therion and the United States.

**“Inventions Under Review”** means those Inventions and patents and applications directed thereto that NIH is investigating to determine whether the United States should be listed as a co-inventor. The Inventions Under Review are set forth on the attachments to Exhibits G, H, and I to this Agreement.

**“Rosenberg CRADA”** means the Cooperative Research and Development Agreement Number 00230 between Therion and NCI through the laboratory of Dr. Steven A. Rosenberg which was terminated on October 31, 2004.

## RECITALS

WHEREAS, on September 26, 1994 NIH entered with Therion into the CRADA for the development of recombinant cancer vaccines (“Vaccines”); and

WHEREAS, Therion filed a petition under chapter 7 of the Bankruptcy Code on November 21, 2006, and Jeffrey L. Burtch (“Burtch”) was appointed as interim trustee. On December 28, 2006, Burtch executed a Report and Certification of Trustee proposing to abandon all scheduled property, stating that “the estate has been fully administered” and requesting that he be discharged from his Trust.” The Bankruptcy Court approved the proposed abandonment on January 11, 2007; and

WHEREAS, NIH is currently investigating the Inventions Under Review; and

WHEREAS, Therion allegedly owes NIH \_\_\_\_\_ in royalties and patent prosecution expenses as of January 31, 2007; and

WHEREAS, Therion may owe NIH termination costs pursuant to Section 10.5 of the CRADA; and

WHEREAS, Therion is willing to provide NIH with the information and materials set forth in this Agreement that are in its possession or under its control that relate to the CRADA and the Rosenberg CRADA; and

WHEREAS, Kranich asserts a security interest in the assets of Therion; and

WHEREAS, Kranich does not object to the transfers by Therion to NIH as provided in this Agreement; and

WHEREAS, Kranich disclaims its security interest in property transferred to NIH pursuant to this Agreement.

**NOW, THEREFORE**, in consideration of the foregoing and the mutual covenants and agreements of the Parties hereto as herein set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Parties, the Parties agree as follows:

1. Therion will transfer to NIH Vaccines, Agents, Subject Data, Research Materials and information or materials in its possession or control related to the CRADA and the Rosenberg CRADA including, but not limited to, the items set forth in the November 20, 2006 letter and appendices thereto attached as Exhibit A to this Agreement. Therion believes that all matters and items referenced in Exhibit A are true and accurate but does

not represent that it has possession and control of all items specified in Exhibit A, or that it can transfer all such items.

2. Therion will execute and date the Notification of Change in Sponsorship regarding the Drug Master Files, in the form attached hereto as Exhibit B.
3. Therion will transfer to NIH the following items to the extent such items are within its possession and control: (1) information and materials needed by NIH to conduct stability testing on existing Vaccines; (2) master seed lots of clinical grade reagents, transfer of vectors and plasmids, and standard operative procedures necessary for NIH to generate more clinical grade and research grade reagents; (3) research grade reagents that have already been manufactured; (4) the vital seed banks, master cultures, and other supporting materials necessary for NIH to ensure that materials are carefully preserved and kept available for future use; and (5) all data related to any Therion-sponsored clinical trials. Therion will use best efforts to provide NIH with access to its server to copy documents and records pertinent to the CRADA and Rosenberg CRADA, but such access shall not include business records, personnel records, records relating to drug development matters for drugs other than those drugs related to the CRADA and Rosenberg CRADA, or general corporate records of Therion. Therion shall arrange to give NIH access to the server which is located at the offices of Mark Leuchtenberger in Cambridge, MA, where NIH employees, contractors, or designees can copy the files as identified herein. Therion shall use best efforts to make access to the server available within five days of the execution of this Agreement, at a time deemed mutually convenient by the Parties. NIH agrees that it will arrange and pay for all costs of copying including, without limitation by bringing an external hard drive to copy the files and providing the personnel who will assist in obtaining information from the server. Therion will be responsible only for ensuring NIH's access to the server and that NIH is given reasonably adequate time to copy the files from the server. NIH shall use its best efforts to copy the files expeditiously. The Parties expect that NIH will need access to the server for a minimum of two days and a maximum of five days to copy the files.
4. Therion will assign to NIH its rights and interests in or to the items set forth in Paragraphs One and Three of this Agreement as well as clinical studies, Vaccines, documents, files, manufacturing processes, Proprietary/Confidential Information, Subject Data, Research Materials, Clinical Data and Results, Agents, Raw Data or other material that specifically relate to the CRADA and/or the Rosenberg CRADA and to execute documents reasonably necessary to achieve such assignments.
5. Therion will execute documents or forms reasonably required by the Office of Cellular, Tissue and Gene Therapies in the NIH or any other government agency, storage facility (including but not limited to Fisher BioServices, Inc., Iron Mountain and Rockland

Immunochemicals, Inc.), or other entity required for the transfer from Therion to NIH of the items set forth in Paragraphs One and Three of this Agreement, in substantially the form as attached hereto as Exhibit C. NIH agrees and acknowledges that Therion shall not be required to perform any additional tasks except making the items available as is and where is to the NIH and, without limiting the foregoing, (1) Therion shall not be required and has not agreed to perform any additional tasks such as assembling or moving the property, preparing reports, compiling data, sorting physical items or documents, (2) NIH's employees, contractors, or designees shall be responsible for performing any clerical or moving tasks and for the costs associated therewith, (3) NIH is responsible for any outstanding costs of storage of the items set forth on Exhibit A to this Agreement at Fisher Bioservices, Inc., Iron Mountain, and Rockland Immunochemicals, Inc. from January 1, 2007 (NIH is not responsible for reimbursing Therion or Kranich for any costs of storage already paid) and (4) NIH shall pay all recording costs, transfer fees, taxes, and any other fees and expenses required to effectuate the transfers and transactions contemplated by this Agreement.

6. Therion will assign to NIH Therion's sole- and jointly-owned rights and interests in any and all Subject Inventions and Co-Owned Inventions and applications or patents directed thereto, arising from the CRADA and/or the Rosenberg CRADA, in the form of Exhibit D to this Agreement.
7. Therion will execute documents to permit NIH to prosecute any and all patents, applications, and/or licenses for Subject Inventions and Co-Owned Inventions that are or were being prosecuted by Therion in the United States and in countries outside of the United States that are directed to any Inventions assigned or conveyed under this agreement in the form of Exhibits E and F to this Agreement.
8. Therion will assign to NIH any and all rights and interests it has or may have in any Inventions Under Review and applications or patents directed thereto that are or were being prosecuted by Therion in the form of Exhibit G to this Agreement.
9. Therion will execute any documents necessary for NIH to prosecute any and all patents, applications and/or licenses for the Inventions Under Review in the United States and in countries outside of the United States, and to effectuate such assignments, in the form of Exhibits H and I to this Agreement.
10. Therion hereby waives any confidentiality obligations of NIH to Therion under the CRADA and the Rosenberg CRADA.
11. Kranich disclaims any and all rights or interests it has, may have, or may have had in any of the items set forth in Paragraphs One and Three of this Agreement, and agrees that Kranich does not have any objection to their transfers and transactions set forth in this

Agreement.

12. The NIH acknowledges that some of the data to be assigned and delivered hereunder has been prepared or developed in conjunction with, or with the input or assistance of, various collaborators throughout the world. The NIH hereby agrees that, upon request of such persons, it shall make such data available to the requesting collaborators to the extent permitted by federal law. Therion specifically consents to the honoring of any such requests without further notice or approval.
13. NIH relinquishes and releases any and all rights and interests it has, may have had, or may have to the \_\_\_\_\_ in royalties and patent prosecution payments owed by Therion to NIH arising from the licenses relating to the CRADA and Rosenberg CRADA, and any other obligations owing by Therion under the CRADA, the Rosenberg CRADA, and such licenses.
14. This Agreement is the result of compromise and settlement and shall not constitute or be construed as an admission, or be utilized or admissible as precedent, evidence or argument in any manner in any proceeding, except as may be necessary to ensure compliance with its terms. It is not to be construed as a concession or admission by any party regarding the subject covered by this Agreement.
15. In consideration of the releases, representations, covenants and obligations herein, the sufficiency of which is hereby acknowledged, Therion fully and finally releases, to the full extent permitted under applicable law, the United States, its agencies, employees, servants, and agents from any and all rights, claims and causes of action (including attorney fees, costs, and expenses of every kind and however denominated), whether known or unknown, or liquidated, contingent or disputed, which Therion has asserted, could have asserted, or may assert in the future against NIH, its agencies, employees, servants, and agents, related to the matters in this Agreement, the CRADA, as amended, the Rosenberg CRADA, any and all interactions among NIH, Therion and Kranich related to the CRADA and the Rosenberg CRADA, and NIH's investigation thereof, except that this release shall not be applicable to efforts to ensure compliance with the terms of this Agreement.
16. In consideration of the releases, representations, covenants and obligations herein, the sufficiency of which is hereby acknowledged, Kranich fully and finally releases, to the full extent permitted under applicable law, the United States, its agencies, employees, servants, and agents from any and all rights, claims and causes of action (including attorney fees, costs, and expenses of every kind and however denominated), whether known or unknown, or liquidated, contingent or disputed, which Kranich has asserted, could have asserted, or may assert in the future against NIH, its agencies, employees, servants, and agents, related to the matters in this Agreement, the CRADA, as amended,

the Rosenberg CRADA, any and all interactions among NIH, Therion and Kranich related to the CRADA and the Rosenberg CRADA, and NIH's investigation thereof, except that this release shall not be applicable to efforts to ensure compliance with the terms of this Agreement.

17. In consideration of the releases, representations, covenants and obligations herein, the sufficiency of which is hereby acknowledged, NIH, its employees, agents, and servants fully and finally release, to the full extent permitted under applicable law, Therion, its agencies, employees, servants, and agents from any and all rights, claims and causes of action (including attorney fees, costs, and expenses of every kind and however denominated), whether known or unknown, or liquidated, contingent or disputed, which NIH has asserted, could have asserted, or may assert in the future against Therion, its employees, servants, and agents, related to the matters in this Agreement, the CRADA, as amended, the Rosenberg CRADA, any and all interactions among NIH, Therion and Kranich related to the CRADA and the Rosenberg CRADA, and Therion's investigation thereof; *provided, however*, that the Parties do not intend this Agreement to release any possible claims that the United States or its agencies other than NIH may have including, but not limited to, claims for tax, fraud or criminal liabilities and *provided further* that this release shall not be applicable to efforts to ensure compliance with the terms of this Agreement. Without limiting the foregoing, the NIH agrees and acknowledges that Therion shall have no further obligations or duties under the CRADA, the Rosenberg CRADA, and any licenses and agreements relating thereto.
18. In consideration of the releases, representations, covenants and obligations herein, the sufficiency of which is hereby acknowledged, NIH, its employees, agents, and servants fully and finally release, to the full extent permitted under applicable law, Kranich, its agencies, employees, servants, and agents from any and all rights, claims and causes of action (including attorney fees, costs, and expenses of every kind and however denominated), whether known or unknown, or liquidated, contingent or disputed, which NIH has asserted, could have asserted, or may assert in the future against Kranich, its agencies, employees, servants, and agents, related to the matters in this Agreement, the CRADA, as amended, the Rosenberg CRADA, any and all interactions among NIH, Therion and Kranich related to the CRADA and the Rosenberg CRADA, and Kranich's investigation thereof; *provided, however*, that the Parties do not intend this Agreement to release any possible claims that the United States or its agencies other than NIH may have including, but not limited to, claims for tax, fraud or criminal liabilities and *provided further* that this release shall not be applicable to efforts to ensure compliance with the terms of this Agreement.
19. Therion makes no representation or warranty regarding its ability to deliver the various terms of property on various lists, or its ownership or other rights in property to be assigned pursuant to various provisions hereof *provided, however*, that Therion represents

and warrants that it will use its best efforts to effectuate the transfer of property specified in this Agreement to the extent such property is in Therion's possession or under Therion's control and *provided further* that Therion represents that it has a good faith belief it has sufficient possession and control of the rights and property to be delivered to NIH under this Agreement to support consideration of the releases herein including a specific belief that Exhibit A to this Agreement accurately represents the location and amount of the items referenced therein. In connection with the foregoing, NIH acknowledges that Therion filed a chapter 7 case which has been closed, that Therion has no funds to perform any obligations hereunder, and that all of the directors of Therion have resigned.

20. Therion assigns its rights and interests to the items set forth in paragraph One, Three and Four of this Agreement and to the Subject Inventions, the Co-Owned Inventions and the Inventions Under Review, and applications or patents directed to any of the foregoing (collectively, the "assigned items") on an "as is" basis, with all faults and defects, and without any warranty of any kind whatsoever. Without limiting the foregoing, Therion disclaims any warranty, express or implied, including any warranty of merchantability, fitness for a particular purpose or non-infringement with respect to the foregoing. Therion makes no warranty, express, implied, statutory or otherwise, that the use, practice or commercial exploitation of anything provided pursuant to this Agreement will not infringe the intellectual property rights of any third party, and, NIH hereby agrees that its use, practice or commercial exploitation of any such subject matter shall be entirely at its own risk.
21. NCI will assume sponsorship of the drug master files, and all responsibilities and obligations relating thereto, including compliance with FDA law and regulations related to the clinical study of the investigational agents, and all reporting and other obligations required by 21 CFR § 312.32 and 312.33 and other applicable regulations. With the transfer of the drug master files, Therion and Kranich hereby disclaim all responsibility for compliance with FDA law and regulations related to the clinical study of the investigational agents and any liability for any claims brought against it relating to or arising from the use or employment of, further transfer and assignment of, or any transaction involving the items and materials transferred hereunder, or to any claim arising from or in connection with any clinical trials or testing of investigational agents or the Vaccines or any other drugs which are derived from the items and materials transferred hereunder. NIH was an active partner in the development of the investigational agents and Vaccines developed under the CRADA and, accordingly, the NIH hereby assumes all liability for any claims brought and assessed against NIH relating to or arising from the use or employment of, further transfer and assignment of, or any transaction involving the items and materials transferred hereunder, or to any claim arising from or in connection with any clinical trials or testing of investigational agents or the Vaccines or any other drugs which are derived from the items and materials



transferred hereunder.

22. Notices. All notices, demands and other communications hereunder shall be in writing or by written telecommunication, and shall be deemed to have been duly given or made: if by hand, immediately upon delivery with receipt acknowledged; if by telecopier, immediately upon sending, provided it is sent during business hours on a business day, but if not, then immediately upon the beginning of the first business day after being sent; if by Federal Express, Express Mail or any other overnight delivery service, on the first business day after timely dispatch; and if mailed by certified mail, return receipt requested, two (2) days after receipt or the return of the notice to sender marked "unclaimed." All notices, requests and demands are deemed to have been duly given or made if delivery is duly attempted and refused and are to be given or made to the parties at the following addresses (or to such other address as either party may designate by notice in accordance with the provisions of this Section):

If to NIH, to:

Mark L. Rohrbaugh, Ph.D, J.D.  
Director, Office of Technology Transfer  
National Institutes of Health  
6011 Executive Blvd., Suite 325  
Rockville, MD 20852

AND

Karen Maurey, M.S.  
Chief, Technology Transfer Branch  
National Cancer Institute  
6210 Executive Blvd., Suite 450  
Rockville, MD 20852

With a copy to:

Dale D. Berkley, Ph.D., J.D.  
NIH Office of the General Counsel  
Bldg. 31, Rm. 2B-47  
Bethesda, MD 20892  
301-451-4911  
Facsimile: 301-402-2528

AND

Frances McLaughlin, Esq.  
Trial Attorney  
Civil Division, U.S. Department of Justice  
1100 L Street, NW, Room 10022  
Washington, DC 20530  
Facsimile: (202) 514-9163

If to Therion, to:

Mr. Michael S. Wyand, DVM, Ph.D.  
President and CEO  
Therion Biologics Corporation  
76 Rogers Street  
Cambridge, MA 02142-1119  
Facsimile: (617) 475-7501

If to Kranich, to:

Kranich Vermögens-und  
Beteiligungsverwaltungs GmbH  
c/o Eagle Advisors, Inc.  
Three World Financial Center  
200 Vesey Street, 25<sup>th</sup> Floor  
New York, NY 10281

With a copy to:

Jonathan M. Landers, Esq.  
Gibson, Dunn & Crutcher LLP  
200 Park Avenue  
New York, NY 10166-0193

- 23. Binding on Successors.** This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors, parent companies, subsidiaries, predecessors and permitted assigns and their agents, employees and representatives. The Parties do not intend this Agreement to have any third party beneficiaries.
- 24. Governing Law.** This Agreement shall be construed in accordance with, and the rights of the parties hereto shall be governed by, federal law, and to any extent not addressed by federal law, by the laws of New York, without taking into account the choice of law provisions of New York law.
- 25. Counterparts.** This Agreement may be executed in counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
- 26. Headings.** The headings of the various sections hereof are for convenience of reference only and shall not affect the meaning or construction of any provisions hereof.
- 27. Severability.** Any provision of this Agreement which is prohibited or unenforceable shall be ineffective only to the extent of such prohibition or unenforceability, without invalidating the remaining provisions hereof.
- 28. Amendment and Waiver.** This Agreement may not be amended or modified without the prior written consent of the Parties. No failure or delay on the part of any Party hereto in exercising any right hereunder shall operate as a waiver of, or impair, any such right. No single or partial exercise of any such right shall preclude any other or further exercise of any other rights. No waiver of any such right shall be effective unless given in writing. No waiver of any such right shall be deemed a waiver of any other right hereunder.
- 29. Entire Agreement.** This Agreement and the Exhibits attached hereto contain the entire agreement between the Parties with respect to the subject matter hereof. This Agreement

and the Exhibits attached hereto supersede all prior discussions and understandings concerning the subject matter hereof.

**30. Expenses.** Each Party to this Agreement shall bear its own legal and other expenses incurred in connection with entering into this Agreement. NIH is solely responsible for any transactional or clerical costs arising in connection with the transfer of items from Therion to NIH hereunder including, without limitation, the items specified in paragraphs three and five of this Agreement, *provided, however*, that NIH will not be required to reimburse Therion or Kranich for the time spent, or any fees expended, relating to the execution of this Agreement and the Exhibits attached hereto. As NIH is solely responsible for the costs of effectuating the transfers contemplated by this Agreement, including any unpaid costs of storage from January 1, 2007 as referenced in paragraph five of this Agreement, Therion will provide NIH with the necessary access to the server referenced in paragraph three of this Agreement at no additional cost to NIH. NIH intends to obtain the balance of the information and materials which are anticipated to be transferred from Therion to NIH under this Agreement by sending its own employees, contractors, or designees to make copies, transfer items, and otherwise perform the tasks necessary to transfer data and property from one party to the other and that Michael Wyand shall only be called upon insofar as it is necessary to access the server specified in this Agreement. Notwithstanding the foregoing, if Therion or the NIH breach this Agreement, then the non-breaching Party shall be entitled to its reasonable attorney's fees and costs in any effort to enforce the provisions of this Agreement, including by further judicial proceedings.

**31. Rules of Interpretation.** The following rules shall apply in the interpretation of this Agreement:

- a. The singular shall include the plural, and the plural shall include the singular.
- b. A reference to any gender shall include each other gender.
- c. A reference to any Section shall, unless otherwise specified, be to a Section of this Agreement.
- d. A reference to any agreement, instrument, organizational document, law, regulation, or other document shall include any amendments, modifications, restatements, or supplements thereof.
- e. The words "include" and "including" shall not be limiting.
- f. The legal maxim that ambiguities in a document shall be construed against the draftsman shall not apply.

**32. Facsimile.** The Parties may enter into this Agreement by exchanging signature pages by facsimile transmission.

**33. Exhibits.** The Parties hereto acknowledge that all Exhibits and attachments thereto are


expressly incorporated into this Agreement and that this Agreement and any Exhibits hereto requiring execution by any Party will be executed contemporaneously.

34. **Timely Performance.** The Parties hereto acknowledge that they will use best efforts to perform this Agreement as quickly as possible.

35. **Effective Date.** This Agreement shall be effective on the date that it has been executed by all of the Parties.

Dated:

2/16/07



Mr. Michael S. Wyand, DVM, Ph.D.  
President and CEO  
Therion Biologics Corporation  
76 Rogers Street  
Cambridge, MA 02142-1119  
Facsimile: (617) 475-7501

Dated:

\_\_\_\_\_

Ekkehart Hassels-Weiler, Attorney in Fact  
Kranich Vermögens- und Beteiligungsverwaltungs  
GmbH  
c/o Eagle Advisors, Inc.  
Three World Financial Center  
200 Vesey Street, 25<sup>th</sup> Floor  
New York, NY 10281

expressly incorporated into this Agreement and that this Agreement and any Exhibits hereto requiring execution by any Party will be executed contemporaneously.

**34. Timely Performance.** The Parties hereto acknowledge that they will use best efforts to perform this Agreement as quickly as possible.

**35. Effective Date.** This Agreement shall be effective on the date that it has been executed by all of the Parties.


Dated:

\_\_\_\_\_

Mr. Michael S. Wyand, DVM, Ph.D.  
President and CEO  
Therion Biologics Corporation  
76 Rogers Street  
Cambridge, MA 02142-1119  
Facsimile: (617) 475-7501

Dated:

2-15-07



Ekkehart Hassels-Weiler, Attorney in Fact  
Kranich Vermögens-und Beteiligungsverwaltungs  
GmbH  
c/o Eagle Advisors, Inc.  
Three World Financial Center  
200 Vesey Street, 25<sup>th</sup> Floor  
New York, NY 10281

Dated:

\_\_\_\_\_

Mark L. Rohrbaugh, Ph.D, J.D.  
Director, Office of Technology Transfer  
National Institutes of Health  
6011 Executive Blvd., Suite 325  
Rockville, MD 20852

Dated:

2/16/07

*Anna D. Barker, Ph.D.*  
with PERMISSION

Anna D. Barker, Ph.D  
Deputy Director for Advanced Technologies and  
Strategic Partnerships, National Cancer Institute  
6210 Executive Blvd., Suite 450  
Rockville, MD 20852


Dated:

\_\_\_\_\_

Frances M. McLaughlin, Esq.  
United States Department of Justice  
Civil Division  
1100 "L" Street, NW Room 10022  
Washington, DC 20005

Dated:

15 Feb 2007



Mark L. Röhrbaugh, Ph.D, J.D.  
Director, Office of Technology Transfer  
National Institutes of Health  
6011 Executive Blvd., Suite 325  
Rockville, MD 20852

Dated:

\_\_\_\_\_

\_\_\_\_\_  
Anna D. Barker, Ph.D  
Deputy Director for Advanced Technologies and  
Strategic Partnerships, National Cancer Institute  
6210 Executive Blvd., Suite 450  
Rockville, MD 20852

Dated:

\_\_\_\_\_

\_\_\_\_\_  
Frances M. McLaughlin, Esq.  
United States Department of Justice  
Civil Division  
1100 "L" Street, NW Room 10022  
Washington, DC 20005

100159155\_4 (Revised - Settlement Agreement).DOC



Dated:

\_\_\_\_\_

\_\_\_\_\_  
Mark L. Rohrbaugh, Ph.D, J.D.  
Director, Office of Technology Transfer  
National Institutes of Health  
6011 Executive Blvd., Suite 325  
Rockville, MD 20852

Dated:

\_\_\_\_\_

\_\_\_\_\_  
Anna D. Barker, Ph.D  
Deputy Director for Advanced Technologies and  
Strategic Partnerships, National Cancer Institute  
6210 Executive Blvd., Suite 450  
Rockville, MD 20852

Dated:

2.15.07


  
\_\_\_\_\_  
Frances M. McLaughlin, Esq.  
United States Department of Justice  
Civil Division  
1100 "L" Street, NW Room 10022  
Washington, DC 20005

Exhibit A



# THERION

B I O L O G I C S

November 20, 2006

Jeffery Schlom, Ph.D.  
Chief, Laboratory of Tumor Immunology & Biology  
National Cancer Institute  
Bldg. 10, Room 8B09  
10 Center Drive, MSC 1750  
Bethesda, MD 20892

**RE: Therion Biologics Corporation Transfer of Assets**

Dear Dr. Schlom:

Therion has transferred six -80°C freezers and one liquid nitrogen freezer, containing clinical trial vaccines and research materials, for storage at Fisher Clinical Services. In addition, Therion has also transferred several hundred boxes of documents for storage at Iron Mountain. Finally, Therion has six vials of the cell line G4G2 in storage at Rockland Immunochemicals, Inc. Please find attached Appendix 1 listing all materials stored at Fisher Clinical Services and Appendix 2 listing all materials storage at Iron Mountain.

Therion has pre-paid Fisher Bioservices, Iron Mountain, and Rockland Immunochemicals, Inc. to hold these materials, which represent valuable assets to Therion, until December 31, 2006. If Fisher Clinical Services, Iron Mountain, or Rockland Immunochemicals, Inc. has not been contacted by Therion Biologics, a Company trustee or judge, or an entity which has acquired Therion assets by December 31, 2006, the ownership and custody of the materials listed in Appendix 1 and Appendix 2 as well as the six vials stored at Rockland Immunochemicals, Inc. will be transferred to the National Cancer Institute. Therion has instructed Fisher Clinical Services, Iron Mountain, and Rockland Immunochemicals, Inc. that you will be the contact person at the National Cancer Institute, if this transfer of materials and/or documents takes place.

Sincerely,

Michael S. Wyand, DVM, Ph.D.  
President and CEO

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
[www.therionbio.com](http://www.therionbio.com)

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer Summary**

Some freezers have been reorganized just prior to shipment

Therefore prior logs are likely inaccurate for non-clinical material.

Freezer F-340 is filled with released clinical material, seed stocks, working virus stocks & master virus stocks

Freezer F-337 is primarily quarantined clinical material, but also has some released clinical material

Freezers F72 & F67 contain QC test samples, stability samples, reagents.... Some of which is not catalogued due to late consolidation.

Two additional freezers contain research stocks, recombinants...

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F340 Seed Stocks**

Virus Seed Stock Inventory			Storage Location			
Product Name	Lot #	Vials	Unit	DP-	Row	
ALVAC(2)-gp100/MART-1/MAGE1-3/TRICOM	1-071102-419	7	F-340	19	3	
ALVAC(2)-NY-ESO-1/TRP-2/TRICOM	1-061002	16	F-340	21	1	
PANVAC-F	1-102202	10	F-340	19	2	
PROSTVAC-F/TRICOM	1-082301	24	F-340	21	2	
PROSTVAC-V/TRICOM	1-071301	16	F-340	21	2	
rF-B7.1	1	2	F-340	23	3	
rF-B7.1	2	32	F-340	23	2	
rF-B7.2	1	24	F-340	23	3	
rF-CEA	1	4	F-340	23	3	
rF-CEA	2	15	F-340	23	3	
rF-CEA(6D)	1	40	F-340	23	2	
rF-CEA(6D)	4	40	F-340	23	3	
rF-CEA(6D)/TRICOM	1	39	F-340	23	3	
rF-DF3(MUC-1)/TRICOM	1	28	F-340	23	3	
rF-GM-CSF	1	37	F-340	23	2	
rF-gp100	1	9	F-340	23	3	
rF-gp100/IL-2	1	26	F-340	23	3	
rF-gp100P209	1A	28	F-340	23	3	
rF-gp100P209	1B	22	F-340	23	3	
rF-MART-1	1	3	F-340	23	2	
rF-MBP	1	19	F-340	23	3	
rF-Mgp100	1	32	F-340	23	2	
rF-MN4	1	15	F-340	23	4	
rF-MUC-1/B7.1	1	30	F-340	23	4	
rF-MUC-1/LFA-3/B7.1	1-092001	29	F-340	14	5	
rF-MUC-1/LFA-3/B7.1	2	29	F-340	14	1	
rF-MUC-1/TRICOM	1	26	F-340	23	3	
rF-NY-ESO-1	1	33	F-340	15	2	
rF-PSA	1	20	F-340	23	3	
rF-PSA/PSMA/TRICOM	1	39	F-340	23	2	
rF-TRICOM	1	39	F-340	23	2	
rF-TYR	1	22	F-340	23	4	
rMVA-PSA/PSMA/TRICOM	1	28	F-340	15	3	
rMVA-TRICOM	1-092001	27	F-340	14	5	
rV-B7.1	2	15	F-340	23	5	
rV-CEA(6D)	1	27	F-340	23	3	
rV-CEA(6D)/TRICOM	1	37	F-340	23	4	
rV-CEA(6D)/TRICOM	2	34	F-340	23	5	
rV-CEA/huB7.1	1	19	F-340	15	3	
rV-gp100/IL-2	1	18	F-340	23	2	
rV-gp100P209	1A	21	F-340	15	3	
rV-gp100P209	1B	22	F-340	15	3	
rV-gp100P209	2A	22	F-340	23	5	
rV-gp100P209	2B	21	F-340	23	5	
rV-MCEA/B7.1	1	12	F-340	23	5	
rV-MCEA/B7.1	2	36	F-340	23	4	
rV-Mgp100	1	25	F-340	23	5	
rV-MUC-1	1	5	F-340	23	5	
rV-MUC-1	2	29	F-340	23	3	
rV-MUC-1	3	22	F-340	15	3	

**APPENDIX 1****Therion Biologics Corporation  
Freezer F340 Seed Stocks**

Virus Seed Stock Inventory			Storage Location		
Product Name	Lot #	Vials	Unit	DP-	Row
rV-MUC-1	4	5	F-340	23	5
rV-MUC-1(DF3)/TRICOM	1	17	F-340	23	1
rV-NY-ESO-1	1	33	F-340	15	1 or 3
rV-PSA(L155)/TRICOM	1	40	F-340	23	2
rV-PSA(L155)/TRICOM	2	17	F-340	14	4
rV-PSA/PSMA	1	15	F-340	23	3
rV-TRICOM	1	49	F-340	23	3
rV-TRICOM	2	29	F-340	23	5
rV-TRP-1	1	18	F-340	23	4
rV-TRP-1	2-071398	46	F-340	23	2
rV-TRP-1	3	46	F-340	23	4
rV-TRP-1	1	19	F-340	23	5
rV-TYR	2	5	F-340	15	3
rV-TYR	1	23	F-340	14	4
TBC-F330	1	11	F-340	14	4
TBC-F349	1	24	F-340	14	3
TBC-F357	1	27	F-340	23	4
TBC-M298	1	28	F-340	23	4
TBC-M309	1	28	F-340	23	4
TBC-M335	1	25	F-340	14	4
TBC-M358	1	25	F-340	14	4
TBC-M381	1-080201	24	F-340	21	2
TBC-M389	1-091301	17	F-340	22	1
TBC-M420	1-080802	15	F-340	19	3
TBC-M420	2-080802	4	F-340	10	1
TBC-MVA	1-1	19	F-340	23	5
TBC-MVA	1-2	19	F-340	23	5
TBC-MVA	1-3	19	F-340	23	5
TBC-MVA	1-4	19	F-340	23	5
TBC-MVA	1-5	19	F-340	23	5
TBC-MVA	1-6	19	F-340	23	5
TBC-MVA	1-7	18	F-340	23	5
TBC-MVA	1-8	19	F-340	23	5
TBC-MVA	1-9	12	F-340	23	4
TBC-MVA	1-10	19	F-340	23	4
TBC-MVA-GUS263	1	25	F-340	15	3
TBC-MVA-GUS417	1-060402	29	F-340	21	1
TBC-vMUC-1	1	16	F-340	14	4
TBC-vTRICOM	2	25	F-340	14	4
TBC-WyΔ37	1	16	F-340	23	4
TBC-WyΔ37	2	3	F-340	14	4

**APPENDIX 1**

**Merion Biologics Corporation  
Freezer F340 MVS**

Master Virus Bank Inventory			Storage Location		
Product Name	Lot #	Vials	Unit	DP-	Row
CDC	1-073198	139	F-340	13	3
PANVAC-V	1-010903	70	F-340	19	2
PROSTVAC-F/TRICOM	1-100401	148	F-340	14	1
PROSTVAC-V/TRICOM	1-081601	13	F-340	14	2-3
rF-B7.1	3-080196	50	F-340	23	2
rF-CEA	2-053196	64	F-340	21	4
rF-CEA(6D)/TRICOM	1-041699	77	F-340	21	5
rF-GM-CSF	1-112095	75	F-340	13	5
rF-gp100/IL-2	1-032196	64	F-340	21	4
rF-gp100P209	1-111497	70	F-340	13	5
rF-MBP	1-042596	119	F-340	21	4-5
rF-Mgp100	1-061397	66	F-340	21	4-5
rF-MN-4	1-121495	64	F-340	21	3
rF-MUC-1/B7.1	2-121898	82	F-340	13	4
rF-MUC-1/B7.1	3-021299	57	F-340	23	1
rF-MUC-1/TRICOM	1-041699	102	F-340	19	3
rF-MUC-1/TRICOM	2-120502	142	F-340	21	1
rF-NY-ESO-1	1-121898	74	F-340	15	1 or 3
rF-NY-ESO-1	2-021299	63	F-340	15	1 or 3
rF-NY-ESO-1	3-040299	61	F-340	15	1 or 3
rF-PSA	1-061396	59	F-340	21	4
rF-PSA/PSMA/TRICOM	1-073099	81	F-340	13	4
rF-TRICOM	1-022699	100	F-340	23,21	1,5
rF-TYR	1-120597	74	F-340	23	1
rV-B7.1	1-052395	58	F-340	13	3
rV-B7.1	2-120296	31	F-340	13	1
rV-CEA(6D)/TRICOM	1-040999	90	F-340	13	1
rV-gp100	1-052395	5	F-340	13	1
rV-gp100/IL-2	1-101596	64	F-340	13	4
rV-gp100P209	1-041798	82	F-340	14	5
rV-MART-1	1	32	F-340	13	4
rV-MCEA/B7.1	1-030698	77	F-340	13	3
rV-Mgp100	1-052397	64	F-340	13	4
rV-MUC-1	5-121997	76	F-340	14,15	5,1
rV-NY-ESO-1	1-121198	64	F-340	15	1 or 3
rV-PSA/PSMA	1-060598	82	F-340	13	1
rV-TRICOM	1-020599	74	F-340	15	1
rV-TRP-1	1-103098	66	F-340	15	1
rV-TYR	2-041798	76	F-340	14	5
TBC-456	TH456MV04E01	137	F-340	15	2
TBC-CEA	2	4	F-340	13	3
TBC-F349	1-051001	139	F-340	14	3-4
TBC-F357	1-050301	137	F-340	15	4
TBC-FPV	1-050495	73	F-340	14	3
TBC-M335	1-051001	130	F-340	19	1
TBC-M358	1-050301	105	F-340	15	4
TBC-M381	1-091301	133	F-340	14	2
TBC-M420	2-022703	66	F-340	19	1
TBC-MN	1	32	F-340	13	4
TBC-MVA	1-030599	49	F-340	13	3
TBC-V/TRICOM	1-062702	147	F-340	19	4
TBC-Wy	3-053195	36	F-340	15	1
TBC-WyΔ37	1-060701	137	F-340	14	1

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F340 WVS**

Working Virus Bank Inventory			Storage Location		
Product Name	Lot #	Vials	Unit	DP-	Row
PROSTVAC-F/TRICOM	1-101801	141	F-340	19	2
PROSTVAC-V/TRICOM	1-083001	117	F-340	14	2
TBC-3B	3-031398	22	F-340	13	1
TBC-CEA	1-082195	45	F-340	15	1
TBC-FPV	1-030702	144	F-340	15	2



**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F340 Released Product**

Released Inventory		Storage Location				
Product Name	Lot #	Vials	Unit	DP-	Row	
PANVAC-F	TH426DP04B008	10	F-340	2	2	
PANVAC-F	TH426DP04B009	217	F-340	2	3	
PANVAC-F (boxed)	McK 04-0321	487	F-340	17-18	-	
PANVAC-F (boxed)	McK 05-0147	136	F-340	17-18	-	
PANVAC-F	3-052203	370	F340			
PANVAC-VF Kit (1ea)	McK 045-146	16 ea	F-340	17-18	-	
PANVAC-V	TH427DP04A003	12	F-340	16	C	
PANVAC-V	1-013003	5	F-340	1	3	
PANVAC-V	TH427DP03A002	19	F-340	1	3	
PANVAC-V	TH427DP04A003	737	F-340	1-2	5,3-1	
PANVAC-V	2-050103	474	F340	9	1-2	
PROSTVAC-F	TH383DP05A001	1490	F337			RELEASE D, But not yet moved from Quaranti ne
				109	A,B,C,D 1-5	Blinded Label Freezer RELEASE D, But not yet moved from Quaranti ne
PROSTVAC-F	TH383DP05A001	608	F337			RELEASE D, But not yet moved from Quaranti ne
				113	A1-5,B1-5,C1-5	Open Label Freezer RELEASE D, But not yet moved from Quaranti ne
PROSTVAC-V	TH382DP05A001	491	F337			RELEASE D, But not yet moved from Quaranti ne
				100	A,B,C 1-5	Blinded Label Freezer RELEASE D, But not yet moved from Quaranti ne
PROSTVAC-V	TH382DP05A001	1191	F337	97,99		RELEASE D, But not yet moved from Quaranti ne
					A,B,C,D 1-5	Open Label Freezer
PROSTVAC (rV-PSA)	5-110797	377	F-340	1	1-2	
PROSTVAC-V	1-092701	48	F-340	1	3	
rF-B7.1	2-111596	628	F-340	11	4-5	
rF-CEA(6D)TRICOM	1-062599	69	F-340	12	2	
rF-CEA(6D)TRICOM	5-112702	1028	F-340	6	2-3-4-5	
rF-GM-CSF	1-012999	245	F-340	12	1	
rF-PSA	2-011400	404	F-340	4	1-2	
rF-TRICOM	2-060499	594	F-340	7	3-4-5	
rF-TRICOM	3-031000	1040	F-340	4	2-3-4-5	
rF-TYR	1-030698	272	F-340	5	1	
rV-gp100P209	1-052298	268	F-340	10	1	
rV-Mgp100	3-040398	275	F-340	6	1	
rV-MUC-1	2-022798	654	F-340	2-3	5,1-2	
rV-TRICOM	1-031299	515	F-340	5	4-5	
rV-TRP-1	3-040299	996	F-340	4	2	
rV-TYR	1-050898	241	F-340	8	1	
TBC-3B	6-082195	88	F-340	9	2	
TBC-CEA	2-042195	270	F-340	9	4	
TBC-FPV	1-110101	444	F-340	10	4-5	
TBC-FPV	2-013102	211	F-340	16	A	Ret'd f/ Fisher 9/13/6
TBC-MVA	1-061401	456	F-340	8	2-3	
TBC-Wy	2-021402	275	F-340	16	B	

SEE RELEASED PROSTVAC in QUARANTINE FREEZER

rV-CEA(6D)TRICOM	1-050799	362
rV-PSA/PSMA	1-072498	440

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F337 Quarantine Product**

Product Name	Lot #	Quarantine Inventory Vials	Freezer	Shelf	Rack	Boxes	Notes
PANVAC-F	TH426DP06C004	148	F337	2	119	A1-5,B1-5	
PANVAC-V	TH427DP05B004	300	F337	4	125	B2-5,C1-5,D1-5	RELEASE D, But not yet moved RELEASE
PANVAC-V	TH427DP05B005	1240	F337	1	110	A,B,C,D 1-5	RELEASE D, But not yet moved RELEASE
PANVAC-V	TH427DP05B006	859	F337	1	109	A,B,C,D 1-5	RELEASE D, But not yet moved RELEASE
PROSTVAC-F	TH383DP05A001	1490	F337	3	113	A1-5,B1-5,C1-5	Open Label
PROSTVAC-F	TH383DP05A001	608	F337	2	100	A,B,C 1-5	Blinded Label
PROSTVAC-V	TH382DP05A001	481	F337	1	97,99	A,B,C,D 1-5	Label CED
PROSTVAC-V	TH382DP05A001	1191	F337	1	61	A1-C4	Protein ELISA Control
rf-gp100/P209	2-052302	837	F337	2	111	D1-D4	PAN-F, Placebo
N-MCEA/B7.1	1-050199	835	In a QC Fzr	2	111	A1-A5	PAN-V Placebo
TBC-FPV	THFPVDP05A002	195	F337	2	111	A1-5,B1-5	PRO-F Placebo
TBC-FPV	THFPVDP05A002	55	F337	3	112	C1-5	PRO-V Placebo
TBC-FPV	THFPVDP05A002	511	F337	2	111		Placebo
TBC-M381	1-110801	139	F337	1	118		Research Lot
TBC-MVA	MFG-082202	15	In a QC Fzr	1			Consisten cy Lot
PANVAC-F	TH426DP06C004	148	F337	2	119	B-D	Consisten cy Lot Blinded labels
PANVAC-F	TH426DP06C006	484	F337	2			Consisten cy Lot Open labels
PANVAC-F	TH426DP06C007	566	F337	2			Consisten cy Lot Blinded labels
PANVAC-F	TH426DP06C008	835	F337	2			Consisten cy Lot Blinded labels
PANVAC-V	TH427DP05B004	300	F337	4			Consisten cy Lot Blinded labels
PANVAC-V	TH427DP05B005	1234	F337	4			Consisten cy Lot Blinded labels
PANVAC-V	TH427DP05B006	853	F337	4			Consisten cy Lot Blinded labels
PANVAC-V	TH427DP05B008	855	F337	4			Consisten cy Lot Blinded labels

**APPENDIX 1**

**Merion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
F67	F67 Shelf 1(top shelf)	QCR26 Box 1	rMVA-Tricom SS Lot2-110801 0.5mL vial	28
F67	F67 Shelf 1(top shelf)	QCR26 Box 1	TBC-M393 SS Lot 1-121801	14
	F67 Shelf 1(top shelf)	1/Box 2	TCB-Wy SS Lot 3-010802	25
	F67 Shelf 1(top shelf)	1/Box 2	TBC-M395 SS Lot 2-012402	17
	F67 Shelf 1(top shelf)	1/Box 3	TCB-Wy MVS Lot 4-013102	63
	F67 Shelf 1(top shelf)	1/Box 4	TBC 3B C181Ve7C-2-1	4
	F67 Shelf 1(top shelf)	1 Box 5	Lysate 3/7/95	45
	F67 Shelf 1(top shelf)	1/box 6	TH427DP05SB003	64
	F67 Shelf 1(top shelf)	1/box 7	TH427DP05SB003	11
	F67 Shelf 1(top shelf)	1/box 8	TH427DP05SB003	64
	F67 Shelf 1(top shelf)	1/box 9	PROSTVAC-F TRICOM Lot 3-040303 Reference STD August 2004	64
	F67 Shelf 1(top shelf)	1/box 10	PROSTVAC-F TRICOM Lot 3-040303 Reference STD August 2004	64
	F67 Shelf 1(top shelf)	1/Box 11	PANVAC-F MVS	3
	F67 Shelf 1(top shelf)	1/Box 12	TH426MV04C01	9 x 10mL
	F67 Shelf 1(top shelf)	1/Box 13	G4G2 Lot 17169C	16
	F67 Shelf 1(top shelf)	1/Box 14	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	1/Box 15	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	1/Box 16	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR26 Box 17	TH426DP04B009	64
	F67 Shelf 1(top shelf)	QCR26 Box 18	PROSTVAC-V DVS-05001	78
	F67 Shelf 1(top shelf)	QCR26 Box 19	PROSTVAC-V DVS-05001	76
	F67 Shelf 1(top shelf)	QCR26 Box 20	PROSTVAC-V DVS-05001	81
	F67 Shelf 1(top shelf)	QCR 1 Box 1	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	81
	F67 Shelf 1(top shelf)	QCR 1 Box 2	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64

**APPENDIX 1****Therion Biologics Corporation****Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 1(top shelf)	QCR 1 Box 3	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 4	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 5	rF-CEA Lot # VAL- 042601-MS3	20
	F67 Shelf 1(top shelf)	QCR 1 Box 6	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 7	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 8	TBC-CEA VAL-042601- MS4	19
	F67 Shelf 1(top shelf)	QCR 1 Box 9	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 10	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 11	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 12	PROSTVAC-V DVS- 05001	25
	F67 Shelf 1(top shelf)	QCR 1 Box 13	TH426DP04B008	51
	F67 Shelf 1(top shelf)	QCR 1 Box 14	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 15	PANVAC-V TH427DP04A004 Reference Std Oct 2004	50
	F67 Shelf 1(top shelf)	QCR 1 Box 16	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 17	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 1 Box 18	PROSTVAC-V/TRICOM Lot 3-041003 Reference std Aug 2004	54
	F67 Shelf 1(top shelf)	QCR 1 Box 19	PROSTVAC-V/TRICOM Lot 3-041003 Reference std Aug 2004	63
	F67 Shelf 1(top shelf)	QCR 1 Box 20	PANVAC-V Lot 2-050103 May 2003 0.3mL	34
	F67 Shelf 1(top shelf)	QCR 7 Box 1	PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	52

**APPENDIX 1****Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 1(top shelf) F67 Shelf 1(top shelf)	QCR 7 Box 2	PROSTVAC-V/TRICOM Lot 3-041003 Reference std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 Box 3	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 Box 4	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7Box 5	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 Box 6	PANVAC-V Lot 2-050103 May 2003	62
	F67 Shelf 1(top shelf)	QCR 7 box 7	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 box 8	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 box 9	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 box 10	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 box 11	PANVAC-V Lot 2-050103 May 2003	64
	F67 Shelf 1(top shelf)	QCR 7 box 12	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	29
	F67 Shelf 1(top shelf)	QCR 7 box 13	PROSTVAC-F/TRICOM lot # 3-040303 Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 box 14	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 7 Box 15	PROSTVAC-V lot DVS- 05001	78
	F67 Shelf 1(top shelf)	QCR 7 box 16	PROSTVAC-V lot DVS- 05001	81

**APPENDIX 1****Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 1(top shelf)	QCR 7 box 17	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR Box 18	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR Box 18	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR Box 19	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR 7 Box 20	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR 29 Box 1	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR 29 Box 2	PROSTVAC-V lot DVS-05001	81
	F67 Shelf 1(top shelf)	QCR 29 Box 3	PROSTVAC-V lot DVS-05001	80
	F67 Shelf 1(top shelf)	QCR 29 Box 4	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 29 Box 5	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 29 Box 6	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 29 Box 7	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	64
	F67 Shelf 1(top shelf)	QCR 29 Box 8	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004	58
	F67 Shelf 1(top shelf)	QCR 29 Box 9	PROSTVAC-V lot DVS-05001	80
	F67 Shelf 1(top shelf)	QCR 29 Box 10	PROSTVAC-V/TRICOM Lot # 3-041003 Reference Std Aug 2004 Benzonase mid ctr. Lot AC06-0105MC Exp 13 Mar 08	63
	F67 Shelf 1(top shelf)	QCR 29 Box 11	CED Protein ELISA VV/VFP Std 1MAD-011204 Std	56
	F67 Shelf 1(top shelf)	QCR 29 Box 12	MID CED Control rf- gp100p209 lot 2-052302	18
	F67 Shelf 1(top shelf)	QCR 29 Box 13	1MAD-011204M	23

**APPENDIX 1****Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 1(top shelf)	QCR 29 Box 14	Low CED Control rf- gp100p209 Lot 2-052302 1MAD-011204L	15
	F67 Shelf 1(top shelf)	QCR 29 Box 15	Benzonase ELISA hgih Control QC06-0104HC exp date 13 March 08	19
	F67 Shelf 1(top shelf)	QCR 29 Box 16	Benzonase ELISA Mid Control QC06-0105MC	12
	F67 Shelf 1(top shelf)	QCR 29 Box 17	Benzonase ELISA low Control Lot 1M06-080	44
	F67 Shelf 1(top shelf)	QCR 29 Box 18	Benzonase ELISA Low Control Lot 1M06-080	18
	F67 Shelf 1(top shelf)	QCR 29 Box 19	Benzonase High Ctr lot QC-06-0104HC	56
	F67 Shelf 1(top shelf)	QCR 29 Box 20	Benzonase low control lot QC06-0106LC	56
	F67 Shelf 1(top shelf)	QCR 36 box 1	FDA Reference Std lot 2- 061499	72
	F67 Shelf 1(top shelf)	QCR 36 Box 2	QC-TBC-Wy Lot 3- 061998	64
	F67 Shelf 1(top shelf)	QCR 36 Box 3	QC-TBC-Wy Lot 3- 061998	23
	F67 Shelf 1(top shelf)	QCR 36 Box 4	rV Lot 2-62691DC Diluted control TBC-3B	61
	F67 Shelf 1(top shelf)	QCR 36 Box 5	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 6	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 7	TBC-Wy MVS lot 4- 013102	78
	F67 Shelf 1(top shelf)	QCR 36 Box 8	Flowpox Titration control TBC-FPV PDR 1	75
	F67 Shelf 1(top shelf)	QCR 36 Box 9	Flowpox Titration control TBC-FPV PDR 1	81
	F67 Shelf 1(top shelf)	QCR 36 Box 10	Flowpox Titration control TBC-FPV PDR 1	81
	F67 Shelf 1(top shelf)	QCR 36 Box 11	TBC-3B Lot 3-101191	45
	F67 Shelf 1(top shelf)	QCR 36 Box 12	TBC-3B Lot 3-101191	64
	F67 Shelf 1(top shelf)	QCR 36 Box 13	TBC-3B Lot 3-101191	64
	F67 Shelf 1(top shelf)	QCR 36 Box 14	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 15	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 16	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 17	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 18	rV Lot 2-62691DC Diluted control TBC-3B	64
	F67 Shelf 1(top shelf)	QCR 36 Box 19	Fowlpox Titration diluted control TBC-FPV PPR1	64

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 1(top shelf)	QCR 36 Box 20	Fowlpox Titration diluted control TBC-FPV PPR1	64
	F67 Shelf 2 (from top)	QCR 34 Box 1	Fowlpox Titration diluted control TBC-FPV PPR1	64
	F67 Shelf 2 (from top)	QCR 34 Box 2	Flowpox Titration diluted control TBC-FPV PDR 1	52
	F67 Shelf 2 (from top)	QCR 34 Box 3	Flowpox Titration diluted control TBC-FPV PDR 1	81
	F67 Shelf 2 (from top)	QCR 34 Box 4	Fowlpox Titration diluted control TBC-FPV PPR1	81
	F67 Shelf 2 (from top)	QCR 34 Box 5	TH426DP06C004	50
	F67 Shelf 2 (from top)	QCR 34 Box 6	TH426DP06C006	49
	F67 Shelf 2 (from top)	QCR 34 Box 7	TH382DP05A001	53
	F67 Shelf 2 (from top)	QCR 34 Box 8	TH382DP05A001	48
	F67 Shelf 2 (from top)	QCR 34 Box 9	TH382DP05A001	37
	F67 Shelf 2 (from top)	QCR 34 Box 10	TH426DP06C008	25
	F67 Shelf 2 (from top)	QCR 34 Box 11	TH426DP06C007	49
	F67 Shelf 2 (from top)	QCR 34 Box 12	TH426DP06C007	22
	F67 Shelf 2 (from top)	QCR 34 Box 13	TH426DP06C007	25
	F67 Shelf 2 (from top)	QCR 34 Box 14	TBC-MVA lot # MFG-102899-D/A	22
	F67 Shelf 2 (from top)	QCR 34 Box 15	TH426DP06C007	49
	F67 Shelf 2 (from top)	QCR 34 Box 16	TH426DP06C006	22
	F67 Shelf 2 (from top)	QCR 34 Box 17	TH427DP06B008	60
	F67 Shelf 2 (from top)	QCR 34 Box 18	TH427DP06B008	50
	F67 Shelf 2 (from top)	QCR 34 Box 19	TH426DP06C006	49
	F67 Shelf 2 (from top)	QCR 34 Box 20	TH426DP06C006	49
	F67 Shelf 2 (from top)	R7 Box 1	TH426DP05C002	50
	F67 Shelf 2 (from top)	R7 Box 2	TH427DP05SB003	50
	F67 Shelf 2 (from top)	R7 Box 3	TH426DP05SC001-B	50
	F67 Shelf 2 (from top)	R7 Box 4	TH427DP05SB002	50
	F67 Shelf 2 (from top)	R7 Box 5	PANVAC-V Lot TH427PDS03A001	7
	F67 Shelf 2 (from top)	R7 Box 6	TH427DP03A001	51
	F67 Shelf 2 (from top)	R7 Box 7	TH427DP03A001	26
	F67 Shelf 2 (from top)	R7 Box 8	TH427DP02A002	21
	F67 Shelf 2 (from top)	R7 Box 9	PROSTVAC-F Lot # DVS-05002	81
	F67 Shelf 2 (from top)	R7 Box 10	PROSTVAC-F Lot # DVS-05002	79
	F67 Shelf 2 (from top)	R7 Box 11	TH427DP03A002	12
	F67 Shelf 2 (from top)	R7 Box 12	TH427DP03A002	62
	F67 Shelf 2 (from top)	R7 Box 13	PROSTVAC-F Lot # DVS-05002	46
	F67 Shelf 2 (from top)	R7 box 14	TH427DP03A002	50
	F67 Shelf 2 (from top)	R7 Box 15	PANVAC-V Lot 2-050103 May 2003	50
	F67 Shelf 2 (from top)	R7 Box 16	TH427DP05SB002	47



**APPENDIX 1****Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
	F67 Shelf 2 (from top)	R7 Box 17	PROSTVAC-F Lot # DVS-05002	66
	F67 Shelf 2 (from top)	R7 Box 18	PROSTVAC-F Lot # DVS-05002	81
	F67 Shelf 2 (from top)	R7 Box 19	TH427DP05SB002	17
	F67 Shelf 2 (from top)	R7 Box 20	TH427DP05SB002	62
		QCR 24 Box 1	TBC-FPV Lot1-110101	22
		QCR 24 Box 2	TH426DP06C008	40
			PROSTVAC-V/TRICOM Lot 3-041003 Reference std Aug 2004	50
		QCR 24 Box 3	TH426DP05SC002	64
		QCR 24 Box 4		
		QCR 24 Box 5	RASVAC-C Lot1-060893A	56
		QCR 24 Box 6	TH426DP06C008	40
		QCR 24 Box 7	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 8	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 9	PROSTVAC-F Lot # DVS-05002	81
			PANVAC-V MVS TH427MV04D01 28.Sept 04	10
		QCR 24 Box 10	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 11	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 12	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 13	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 14	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 15	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 16	TH426DP05SC002	43
		QCR 24 Box 17	PROSTVAC-F Lot # DVS-05002	81
		QCR 24 Box 18	PROSTVAC-F Lot # DVS-05002	81
			PROSTVAC-F/TRICOM Lot 3-040303 Reference std Aug 2004	50
		QCR 24 Box 19	TH427DP06B008	60
		QCR 24 Box 20		
		R63 Box 1	PANVAC-F Lot 3-052203	50
		R63 Box 2	TH426PD03B002	50
		R63 Box 3	TH426PD03B001	50
		R63 Box 4	PANVAC-F Lot 4-060503 rF-CEA(6D)/TRICOM Lot # 5-112702	48
		R63 Box 5		48

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
		R63 Box 5	PANVAC-F MVS Lot # 1-011603	10
		R63 Box 6	PANVAC-V Lot # 1-0103003	48
		R63 Box 7	PANVAC-F Lot # 2-022703	50
		R63 Box 8	PROSTVAC-V/TRICOM Lot # 2-032102	48
		R63 Box 9	rF-MUC-1/TROCOM MVS Lot 2-120502	10
		R63 Box 9	PANVAC-V SS Lot # 1-110102	5
		R63 Box 9	TBC-f/TRICOM SS lot # 1-110702	5
		R63 Box 10	PANVAC-V MVS lot # 1-010903	10
		R63 Box 10	PANVAC-V SS lot # 2-112202	5
		R63 Box 11	rF-MUC-1/TRICOM Lot # 3-012303	50
		R63 Box 12	TBC Wy Lot # 2-021402	50
		R63 Box 13	PANVAC-F SS Lot # 1-102202	5
		R63 Box 14	PROSTVAC-F/TRICOM Lot # 2-020702	46
		R63 Box 15	TBC-FPV lot # 2-012102	50
		R63 Box 16	rF-gp100P209 lot # 3-100302	48
		R63 Box 17	TH426DP04B009	50
		R63 Box 18	rF-gp100P209 lot 2-052302	64
		R63 Box 19	rF-gp100P209 lot 2-052302	64
		R63 Box 20	TH426DP04B007	55
	F67 Shelf 2 (from top)	QCR35	Varrious Plasmids Whole rack	
	F67 Shelf 3 (from top)	QCR35	Varrious Plasmids Whole rack	
	F67 Shelf 3 (from top)	R62 boxes 1-7	Varrious Plasmids	
	F67 Shelf 3 (from top)	R62 box 8	BSA Control Lot 2-051700	Many tubes
	F67 Shelf 3 (from top)	R62 Box 9	BSA-Control Lot 2-051700	Many tubes
	F67 Shelf 3 (from top)			
	F67 Shelf 3 (from top)	QCR 32 all boxes	Varrious plasmids	
	F67 Shelf 3 (from top)	R64 Box 1	PANVAC-V SS lot # 2-112202	16
	F67 Shelf 3 (from top)	R64 box 2	PANVAC-V SS lot # 1-112202	27

**APPENDIX 1****Therion Biologics Corporation  
Freezer F67 Misc QC**

Freezer #	Shelf #	Rack #	Product	# Vials
			TBC-r/TRICOM SS lot #1- 110702	14
	F67 Shelf 3 (from top)	R64 Box 2	TH427DP03A001	50
	F67 Shelf 3 (from top)	R64 Box 3	rF-MUC-1TRICOM Lot #3- 012303	9
	F67 Shelf 3 (from top)	R64 Box 4	rF-MUC-1/TRICOM Lot #3-012303	64
	F67 Shelf 3 (from top)	R64 Box 5	rF-MUC-1TRICOM Lot #3- 012303	63
	F67 Shelf 3 (from top)	R64 Box 6	rF-MUC-1TRICOM Lot #3- 012303	64
	F67 Shelf 3 (from top)	R64 Box 7	rF-MUC-1TRICOM Lot #3- 012303	63
	F67 Shelf 3 (from top)	R64 Box 8	rF-MUC-1TRICOM Lot #3- 012303	64
	F67 Shelf 3 (from top)	R64 Box 9	rF-MUC-1TRICOM Lot #3- 012303	64
	F67 Shelf 3 (from top)	R64 Box 10	PANVAC-F MVS Lot # 1- 011603	16
	F67 Shelf 3 (from top)	R64 Box 11	PANVAC-F MVS Lot # 1- 011603	56
	F67 Shelf 3 (from top)	R64 Box 12	rF-MUC-1TRICOM Lot #3- 012303	64
	F67 Shelf 3 (from top)	R64 Box 13	PANVAC-F MVS Lot # 1- 011603	24
	F67 Shelf 3 (from top)	R64 Box 14	rF-MUC-1TRICOM Lot #3- 012303	53
	F67 Shelf 3 (from top)	R64 Box 15	rF-gp100P209 Lot # 2- 052302	18
	F67 Shelf 3 (from top)	R64 Box 16	rF-gp100P209 Lot # 2- 052302	57
	F67 Shelf 3 (from top)	R64 Box 17	TH382DP05A001	50
	F67 Shelf 3 (from top)	R64 Box 18	TH382DP05A001	27
	F67 Shelf 3 (from top)	R64 Box 19	TH426DP06C004	52
	F67 Shelf 3 (from top)	R64 Box 20	TH427DP05SB001-A	50
		R65 Box 1	TH427DP05SB001-A	28
		R65 Box 2	PROSTVAC-F/TRICOM lot # 3-040303 Aug 2004	29
		R65 Box 3		

Shelves 4 & 5 - were not  
cataloged, but include  
misc.stability Samples,  
reagents...

**APPENDIX 1**

**Therion Biologics Corporation  
Freezer F72 Misc QC**

Freezer F72 was not catalogued due to inadequate time.

The freezer contains miscellaneous stability samples, reagents...

Items were consolidated from other QC freezers and have log sheets in original freezer books.

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
433084173	RA: Box 4 - rF-CF rV-MUC-1, rF-CEA(6D) TRICOM
433084174	RA: Box 5 - rF-gp100P209 / MF-7943; rV-TYR / MF-8167; rF-TYR / MF-8022; rF-B7.1 / MF-7468; rV-B7.1 / MF-7733
433084175	RA: Box 6 - rF-TRICOM / MF-8934; rV-TRICOM / MF-8570; rF-PSA / MF-7421
433084176	RA: Box 7 - rV-PSA ("Prosvac") / MF-6670; rV-PSA / MF-5537; rV-PSA / MF-7646; TBC-CEA / MF-5029
433084177	RA: Box 8 - rV-rF-CEA(6D)/TRICOM and rV-MUC-1IND 10789
433084178	RA: Box 9 - TBC-Wy; TBC-FPV/TBC-CEA / MF-6587
433084179	RA: Box 10 - PANVAC Misc. (Orphan Drug, USAN, CAS, eCTD pilot)
433081480	RA - Box 11 - PANVAC IND 11139 Chron
433084181	RA - Box 12 - PANVAC IND, Serials No. 0001 - No.0008
433084182	RA - Box 13 - PANVAC IND, Serials No. 0009 - No. 0014
433084183	RA - Box 14 - PANVAC IND, Serials No. 0015 - No. 0032
433084184	RA - Box 15 - PANVAC IND, Serials No. 0033 - No. 0089
433084185	RA - Box 16 - PANVAC IND, Serials No. 0090 - No. 0106 vol. 1-8 (of 11)
433084186	RA - Box 17 - PANVAC IND, Serials No. 0106 (vol. 9 -11) - No. 0161
433084187	RA - Box 18 - PROSTVAC IND 10428 Chron File
433084188	RA - Box 19 - PROSTVAC IND, Pre-IND Mtg Pkg, Serial No. 0000 vol. 1 - 6
433084197	RA - Box 20 - PROSTVAC IND Serials No. 0001 - No.0022
433084198	RA - Box 21 - PROSTVAC IND Serials No. 0023 - 0058
433084199	RA - Box 22 - PROSTVAC IND Serials No. 0059 - 0071
433084200	RA - Box 23 - PROSTVAC IND Serials No. 0072 - 0074
355555661	Q: PROSTVAC-FTRICOM
355555662	Q: Method Validation
355555663	Q: PANVAC-V Lot 1 & Lot 2
355555664	Q: PROSTVAC-VTRICOM
355555665	Q: PROSTVAC-VTRICOM
355555666	Q: PROSTVAC-V
355555667	Q: Old Batch Records, rV-MEA/B7.1, rMVA-PSA/TRICOM, etc.
355555668	Q: Old Batch Records, rV-MUC, etc.
355555669	Q: Lab Notebooks rTRP-1, rV-TYR, rF-TYR
355555670	Q: rF-PSA Old Batch Records
355555671	Q: rV TRICOM Lot 1, rFMUC-1 B7 Lot 1
355555672	Q: TBC-CEA MUS+SS, PROSTVAC Lot2 MUS+SS rFCEA SS MUS, rFB7 SS MUS
355555200	Q: Misc. QC
355555199	Q: Misc. QC
355555197	Q: QC Binders
355555196	Q: QC Binders
355555195	Q: PANVAC-F Filled 2004
355555194	Q: PANVAC-V Filled 2004
355555193	Q: PANVAC-V Filled 2005

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
355555192	Q: PANVAC-VF Filled 2005
355555191	Q: rV rF Lots
355555190	Q: PD Reports
355555189	Q: TBC RA's TrVac
355555188	Q: Stability Batch Records PANVAC-F
355555187	Q: Stability Batch Records PANVAC-V
355555711	Q: Equipment Validation
355555712	Q: Equipment Validation
355555713	Q: PD Lab Notebooks
355555717	Q: PANVAC-F, PANVAC-V Master Virus Batch Records
355555716	Q: Drug Substance Batch Records - not filled to DP
355555715	Q: PANVAC-F
355555714	Q: Method Validation
355555708	Q: PANVAC-F Filled 2004
355555709	Q: PANVAC-F Filled 2004
355555710	Q: PANVAC-F Filled 2004
355555659	Q: Cleaning Validation
355555660	Q: QC Test Results TH427DS04A009, TS1 MASON Study Reports
355555186	Q: Stability Batch Records PANVAC-F
355555185	Q: TBC CEA Lot 2
355555184	Q: Product Batch Record TBC M381
355555181	Q: TBC CEA MVS 3B M309 M389
355555180	Q: Stability Batch Records
355555179	Q: TRICOM rF-MUC, rF-CEA, rF-TRP
355555673	Q: rFMPG100, rFgp100P209, rVgp100P209
355555674	Q: CM235, RASVAC, RASVACTW
355555675	Q: PROSTVAC TBC CEA
355555676	Q: TBC-WY Research Lots
355555677	Q: HIV, PROSTVAC, TBC-3B, TBC/PSA
433084149	Q: QC Test Records In Process
433084150	Q: QC Test Records In Process
433084151	Q: 2003 EM
433084152	Q: 2003 EM
433084153	Q: QC Test Records In Process
433084154	Q: 2003 Stability
433084155	Q: Manufacturing Equipment Logs
433084156	Q: PROSTVAC TH382D505A001
433084195	Q: PROSTVAC
436614296	Q: TBC-FPV THFPVDP05A002

Therion Biologics Corporation  
 Customer ID#: B1955

APPENDIX 2

Barcode	Contents
436614297	Q: TBC-FPV
436614298	Q: TBC
436614299	Q: TBC
436614378	Q: QC Binders - 2005 Environmental Monitoring
436614379	Q: QC Binders - 2005 Environmental Monitoring
436614380	Q: QC Binders
436614381	Q: QC Binders
436614397	Q: QC Binders, Biosafety Cabinets - 2005
436614382	Q: QC Binders Micro Reposrts Bac & Fungal
436614383	Q: QC Binders - Water Testing 2005
436614384	Q: QC Files BSC Charts
436614385	Q: QC Files Freezers & Pipets
436614396	Q: QC Files Pipet Calibrating
436614386	Q: QC Files
436614387	Q: QC Files Incubator Charts
436614388	Q: QC Files
436614287	Q: Old QC
436614288	Q: 2003 EM
436614289	Q: Misc. QC
436614290	Q: Stability Protocol
436614291	Q: EM
436614292	Q: EM
436614293	Q: EM
436614294	Q: EM
436614295	Q: EM
436614300	Q: TBC FPV rFMUC
436614389	Q: QC Files Temp Charts
436614390	Q: QC Binders
436614396	Q: QC Water Testing
436614391	Q: Legal Files
436614392	Q: QC Binders - EM
436614393	Q: QC Raw Material
436614394	Q: Biosafety Cabinets
436614395	Q: BSC - EM QC
433084145	Q: 2003 EM QC
433084146	Q: QC PANVAC consistency testing
433084147	Q: QC PANVAC consistency testing
433084148	Q: QC PANVAC consistency testing
436614449	Q: Raw Material Records MR-3540 - ML-6000

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
436614448	Q: Raw Material Records MR-3540 - MQC-8455
436614447	Q: Raw Material Records MQC-2460 - MQC-5550
436614446	Q: Raw Material Records MQC-5895 - MQC8450
436614445	Q: Raw Material Records MR-7200 - MQC-2457
436614443	Q: Raw Material Records MR-4400 - MR-7100
436614442	Q: Raw Material Records MN-5190 - MN-8405
436614441	Q: Raw Material Records MN-0001 - MN4599
436614440	Q: Raw Material Records MN-4630 - MN5150
436614439	Q: Raw Material Records MR-0001 - MR-4250
436614429	Q: MS3&4 Equipment Validation Vac Doc PANVAC Protocol Drug Substance
436614430	Q: MS3&4 Equipment Validation WFI Addendum/Reagent WS310Q Protocol Binney QE-020
436614431	Q: MS3&4 Equipment Validation DU6400Q Warm Room O&M WFI O&M WFI System
436614432	Q: MS3&4 Equipment Validation Protocol (VAS) 336, 346, 363, 345, 347, 364
436614433	Q: MS3&4 Equipment Validation Protocol
436614434	Q: MS3&4 Equipment Validation Protocol Performance Qualification
436614435	Q: MS3&4 Equipment Validation Protocol
436614436	Q: MS3&4 Equipment Validation Protocol
436614437	Q: MS3&4 Equipment Validation Protocol
436614438	Q: MS3&4 Equipment Validation Protocol
436614419	Q: PRO-002 McKesson BR's
436614418	IT: Server Backup Tapes 2005
436614416	IT: Misc. QA MFG Paperwork
436614417	IT: Server Backup Tapes Jan-Oct 2006
436614359	Q: Misc. Log Records
436614277	Q: Buffer Batch Reports
436614276	Q: Buffer Batch Records
436614275	Q: Misc. Log Records
436614274	Q: Trackwise Protocols ECTO Builder Protocols
436614273	Q: Trackwise Protocols ECTO Builder Protocols
436614272	Q: Change Controls
436614271	Q: Deviations
436614270	Q: Deviations
436614269	Q: Vendor Files A04002 - EAO4022
436614268	Q: Drug Substance BR's, Monthly EM Reports, Quarantine Release Docs
436614267	Q: Investigation, Internal Audits, CAPA Reports
436614266	Q: Investigation, Internal Audits, CAPA Reports
436614265	Q: Training Files T-Z
436614264	Q: Confidential OIR04004, File Folder Labels
436614354	Q: In Process In Review Batch Records



**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
436614353	Q: Performance Qualification
436614352	Q: In Process In Review Batch Records
436614351	Q: In Process In Review Batch Records
436614350	Q: MR
436614349	Q: Engineering Study Protocol
436614348	Q: Engineering Study Protocol
436614347	Q: Deviations DO5
436614346	Q: Obsolete Protocols
436614345	Q: Protocol V Deviations D04
436614332	Q: Deviations D05 Present
436614331	Q: NC MR Log
436614330	Q: PN PROSTVAC SAVI Drug Prod.
436614329	Q: Documentation Biennial Review
436614423	Q: Warehouse: Paperwork Material Specs.
436614424	Q: Warehouse Paperwork
436614425	Q: Material Specs MS-054, MS-059
436614426	Q: Warehouse Paperwork SOP Book 48C Material Specs
436614427	Q: Material Specs MS-0120, MS-168
436614428	Q: Material Specs MS-060, MS-119
436614422	Q: Misc. Warehouse Paperwork
436614420	Q: Misc. QC info from Warehouse
436614421	Q: Material Files SPAFAS PROSTVAC-P3 MT-0020
436614358	Q: Misc. Equip. Logs & Charts
436614357	Q: Misc. Equip. Logs & Charts
436614356	Q: Methods Validation PANVAC-V, PANVAC-F
436614355	Q: Cleaning Logs
436614363	Q: TPI Log, TPI47-TPI 79
436614360	Q: TPI Log, TPI1 - TRI45
436614361	Q: Vendor Files AO-3028 - EA05016
436614362	Q: Vendor Files EA 04018 - A03023
436614333	Q: Vendor Files AO3027 - AO3024
436614334	Q: Training Files F-K
436614335	Q: Training Files C-F
436614344	Q: Training Files A-C
436614343	Q: Training Files P-T
436614342	Q: Training Files M-P
436614341	Q: Training Records L-M
436614340	Q: Original Specs: MS-0004 - MS-0070
436614339	Q: Original SOPs IA-0001 - MF-0021

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
436614338	Q: Original SOPs BA-0001 - FA0028
436614337	Q: Original SOPs QA-0033 to QC-0095
436614336	Q: Original SOPs MF-0072 to MF-0083
436614309	Q: Original SOPs QC-0130 to VA-0005
436614310	Q: Original SOPs MT-0004 to QA-0032
436614311	Q: Part # PN-0391 to PM-0415
436614312	Q: Original SOPs QC-0096 to QC-0129
436614313	Q: Original Specs MS-0072 to MS-0134
436614314	Q: MP-BR's MPBR TOC to MPBR 067
436614315	Q: Part # PN-0035 to PN-0070
436614316	Q: Part # PN-0001 to PN-0034
436614317	Q: Original Specs: MS-0135 to PS-0019
436614318	Q: Part # PN-0140 to PN-0181
436614319	Q: Part # PN-0015 to PN-0139
436614320	Q: Part # PN-0071 to PN-0113
436614328	Q: Documentation Log Books, Equipment Protocols
436614327	Q: Documentation Log Books B-V
436614326	Q: Documentation Log Books EAR 04
436614325	Q: Misc. Documentation Log Books
436614324	Q: Documentation Log Books Temporary Departature EAR
436614323	Q: Documentation Log Book EAR
436614308	Q: GLP- Study Files
436614307	Q: Part # PN - 0378 - PN-0389
436614306	Q: Part # PN-0350 - PN-0377
436614305	Q: Part # PN-0319 - PN-0349
436614304	Q: Part # PN-0182 - PN0228
436614303	Q: Part # PN-0229 - PN-0274
436614302	Q: Part # PN-0275 - PN-0318
436614301	Q: Vendor Files EA05020 - EA04031
436614322	Q: Misc. QC
436614251	Q: Misc. QC
436614252	Q: Misc. QC
436614253	Q: Misc. QC
436614254	Q: Misc. QC
436614255	Q: Misc. QC
436614256	Q: Misc. QC
436614257	Q: QC EM
436614258	Q: QC EM
436614259	Q: QC EM

**APPENDIX 2**

Barcode	Contents
436614260	Q: QC EM
436614261	Q: QC EM
436614274	Q: Stability Data
436614275	Q: Stability Data
436614276	Q: Stability Data
436614277	Q: Stability Data
436614278	Q: Stability Data
436614279	Q: Stability Data
436614280	Q: Stability Data
436614281	Q: Stability Data
436614282	Q: QC Equipment Logs
436614283	Q: Part assign
436614284	Q: Empty Notebook
436614285	Q: Empty Notebook
436614286	Q: Empty Notebook
436614262	Q: QC EM
436614263	Q: Raw Data MFG-QC Testing
436614264	Q: Raw Data MFG-QC Testing
436614265	Q: Raw Data MFG-QC Testing
436614266	Q: Raw Data MFG-QC Testing
436614267	Q: Raw Data MFG-QC Testing
436614268	Q: Raw Data MFG-QC Testing
436614269	Q: Raw Data MFG-QC Testing
436614270	Q: Raw Data MFG-QC Testing
436614273	Q: EM data
436614272	Q: EM data
436614271	Q: EM data
355555699	Q: Old Batch Records
433084039	R&D
433084093	R&D
433084094	R&D
433084095	R&D
433084096	R&D
433084048	R&D
433084049	R&D
433084050	R&D
433084052	R&D
433084051	R&D
433084101	R&D

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
433084102	R&D
433084030	R&D
433084032	R&D
433084033	R&D
433084034	R&D
433084040	R&D
433084041	R&D
433084042	R&D
433084043	R&D
433084044	R&D
433084045	R&D
433084046	R&D
433084047	R&D
433084018	R&D
433084019	R&D
433084021	R&D
433084022	R&D
433084023	R&D
433084031	R&D: IACUC
433084024	R&D
433084025	R&D
433084026	D&O Insurance
433084027	R&D
433084028	R&D: PROSTVAC PM Info
433084029	R&D
433084104	R&D: Clinical Trials
433084105	R&D: Clinical Trials
433084106	R&D: Clinical Trials
433084107	R&D: Clinical Trials
433084108	R&D: Clinical Trials
433084111	R&D: Clinical Trials
433084112	R&D: Fisher BioServices Freezer, LN2 Logs
433084013	R&D
433084014	R&D
433084015	R&D
433084016	R&D
433084017	R&D
355447635	R&D
355447636	R&D

Therion Biologics Corporation  
Customer ID#: B1955

APPENDIX 2

Contents

Barcode	Contents
355447637	R&D
433084113	R&D
433084114	R&D
433084115	R&D
433084116	R&D
433084117	R&D
433084118	R&D
433084119	R&D
433084120	R&D
433084109	R&D
433084110	R&D
355447623	R&D
355447624	R&D
355447625	R&D
355447626	R&D
355447627	R&D
355447628	R&D
355447629	R&D
355447630	R&D
355447631	R&D
355447632	R&D
355447633	R&D
355447634	R&D
355447611	R&D
355447612	R&D
355447613	R&D
355447614	R&D
355447615	R&D
355447616	R&D
355447617	R&D
355447618	R&D
355447619	R&D
355447620	R&D
355447621	R&D
355447622	R&D
433084125	R&D
433084126	R&D
433084127	R&D
433084128	R&D

Therion Biologics Corporation  
 Customer ID#: B1955

**APPENDIX 2**

**Contents**

Barcode	Contents
355447602	R&D
355447603	R&D
355447604	R&D
355447605	R&D
355447606	R&D
355447607	R&D
355447608	R&D
355447609	R&D
355447610	R&D
433084129	R&D
433084130	R&D
433084131	R&D
433084132	R&D
433084133	R&D
433084134	R&D
433084135	R&D
433084136	R&D
433084121	R&D
433084122	R&D
433084123	R&D
433084124	R&D
436614321	R&D
436614403	R&D
436614404	R&D
436614405	R&D
436614406	R&D
436614407	R&D
436614408	R&D: Radiation Safety
436614409	R&D
436614410	R&D: TBC-M358 Testing, Stability Testing M335, M358, F359, F357
436614411	R&D: TBC-357 SS/MVS, TBC-349 SS/MVS, Rabbit Tox
436614412	R&D: TBC-M335 SS/MVS/Product Lot, TBC-M358 SS/MVS/Product Lot
436614413	R&D: TBC-M335, TBC-F349, TBC-M358, TBC-357 Master Files
436614414	R&D: TBC-MVA
436614415	R&D: Copies TBC-M335, TBC-M358, TBC-F349, TBC-F357
433084086	R&D
433084087	R&D
433084088	R&D
433084089	R&D

Therion Biologics Corporation  
Customer ID#: B1955

APPENDIX 2

Contents

Barcode	Contents
433084090	R&D
433084091	R&D
433084092	R&D
436614398	R&D
436614399	R&D
436614400	R&D
436614401	R&D
436614402	R&D
433084074	R&D
433084073	R&D
433084082	R&D
433084083	R&D
433084075	R&D
433084076	R&D
433084077	R&D
433084078	R&D
433084079	R&D
433084080	R&D
433084081	R&D
433084084	R&D
433084085	R&D
433084097	R&D; Module 3
433084098	R&D; Module 3
433084099	R&D; Module 1
433084103	R&D; Module 4
433084100	R&D; Module 4
433084053	R&D; Module 4
433084054	R&D; Module 4
433084055	R&D
433084056	R&D
433084057	R&D
433084061	R&D
433084062	R&D
433084063	R&D
433084064	R&D
433084065	R&D
433084066	R&D
433084067	R&D
433084068	R&D

**Therion Biologics Corporation  
Customer ID#: B1955**

**APPENDIX 2**

Barcode	Contents
433084058	R&D
433084059	R&D
433084060	R&D
433084069	R&D
433084070	R&D
433084071	R&D
433084072	R&D
355447638	CL: PAN-003 Clinical
355447639	Clinical
355447640	CL: PAN-003 Clinical
355447641	CL: PAN-003 Clinical
355447642	CL: PAN-003 Clinical
355447643	CL: PAN-003 Clinical
355447644	CL: PAN-003 Clinical
355447645	CL: PAN-003 Clinical
355447646	CL: PAN-003 Clinical
355447647	CL: PAN-003 Clinical
355447648	CL: PAN-003 Clinical
355447649	Clinical Misc.
355447650	Clinical Misc.
355447651	Clinical Misc.
355447652	Clinical Misc.
355447653	Clinical Misc.
355447654	Clinical Misc.
355447655	Clinical Misc.
355447656	Clinical Misc.
355447657	CL: PRO-002
355447658	CL: PRO-002
355447659	CL: PRO-002
355447660	CL: PRO-002
355447661	CL: PRO-002
355447662	CL: PRO-002
355447663	CL: PRO-002
355447664	CL: PRO-002
355447665	CL: PRO-002
355447666	CL: PAN 1-1
355447667	CL: PAN 1-1
355447668	CL: PAN 1-1
355447669	CL: PAN 1-1



**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

<b>Barcode</b>	<b>Contents</b>
355447670	CL: PRO-002
355447671	CL: P1-4
355447672	CL: P1-4
355447673	CL: PAN-003 Clinical
355447674	Clinical Misc.
355447675	CL: PRO-002
355447676	CL: PRO-002
355447677	CL: PRO-002
355447679	CL: PRO-002
355447678	CL: PRO-002
355447680	CL: Clinical Safety
355447681	CL: Clinical Safety
355447682	CL: Clinical Safety
355447683	CL: Clinical Safety
355447684	CL: Clinical Safety
355447685	CL: Clinical Safety
355447686	CL: Clinical Safety
355447687	CL: Clinical Safety
355447688	Clinical Misc.
355447689	Clinical Misc.
355447690	Clinical Misc.
355447691	Clinical Misc.
355447692	Clinical Misc.
355447693	Clinical Misc.
355447694	CL: Clinical Safety
355447695	CL: PAN-003 Clinical
355447696	CL: PAN-003 Clinical
355447697	CL: PAN-003 Clinical
355447698	CL: PAN-003 Clinical
355447699	CL: PAN-003 Clinical
355447700	CL: PAN-003 Clinical
355447701	CL: PAN-003 Clinical Draft CSR
433084035	Clinical Misc.
433084036	Clinical Misc.
433084037	Clinical Misc.
433084038	CL: Tom Schuetz (CMO) Office
453221554	Q: QC Logs 2006 Vaccinia Test Samples, DS, DP
453221553	Q: QC Log Books 2006 - Stability Samples, Retains Research Lots BSA ELISA
453221552	Q: QC Logs 2006 Fowlpox Test - QC Test Samples, DS, DP

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

Barcode	Contents
453221151	Q: QC Logs 2006 Retains, MVA Inventory, Critical Reagents, F19, Sample Tracking, CEP&ELISA reagents
453221157	Q: 2004 Time and Attendance Wks 27-52
355555182	Q: Freezer Inventory Logs Current
355555697	Q: Materials & Sample Submission Log Books
355555698	Q: Misc. QA - PNs: Equip Logs, Autoclave Logs, Archive Logs, FBS Qual Study
355555700	Q: Misc. QA Temp Charts, Training, Buffer Records, M57&M38 Usage Logs
355555701	Q: QC Binders From Lab
355555702	Q: QC Binders From Lab
355555703	Q: QC Binders From Lab
355555704	Q: QC Binders From Lab
355555705	Q: QC Binders From Lab
355555176	Q: E-Tops 2003
355555177	Q: Facility Ops
453221151	Q: Facility Ops
453221152	Q: Safety Radiation
453221153	Q: BBP Quiz's Vaccination Forms
453221154	Q: EBI Proposals
453221155	Q: PANVAC F Radiation Reports
355555707	Q: GLP - Study Files
355555706	Q: Misc. Equip. Docs
453221156	RA: rVMpg100, MF 8089
323212958	RA: TBC-3B
323212959	RA: rFGp100, rVgp100, rFMgp100P209, rVMgp100P209
355555691	Q: Raw Materials
355555692	Q: Raw Materials
355555693	Q: Stericycle Manifests
355555694	Q: Stericycle/Waste Manifests
355555695	Q: Certificate of Analysis
355555696	Q: QC Testing
355555183	Q: MSDS S-Z Accident Reports
355555658	Q: MSDS H-R
355555657	Q: MSDS A-G
355555656	Q: EAP PLAN Sewer Permits
355555655	Q: Radiactive
355555652	Q: Permits Misc. Safety
355555178	Q: Safety Documents
355555182	Q: Freezer Inventory Logs
355555678	Q: Equip Certs
355555679	Q: Equipment Certs

**APPENDIX 2**

**Therion Biologics Corporation  
Customer ID#: B1955**

<b>Barcode</b>	<b>Contents</b>
355555680	Q: Sample Submission
355555681	Q: Raw Materials
355555683	Q: Raw Materials
355555684	Q: Raw Materials
355555685	Q: Raw Materials
355555686	Q: Raw Materials
355555687	Q: Raw Materials
355555688	Q: Equipment Certs
355555689	Q: Equipment Certs
355555690	Q: Raw Materials

PHONE: (610) 389-1008 • FAX: (610) 387-7826

INVOICE DATE: 11/16/2005 CUST.# Therion

S  
O  
L  
D  
T  
O

Therion Biologics  
 Accounts Payable  
 76 Rogers Street  
 Cambridge, MA 02142

S  
H  
I  
P  
T  
O


Therion Biologics  
 Attn: Dr. Kimbely Zimnick  
 76 Rogers Street  
 Cambridge, MA 02142

PO # 111606TAE Ref # 120892

ORDERED BY Lisa Sperry 6174757506

DATE RECEIVED	DATE WANTED	SALESMAN	TERMS	VIA		
11/16/2005	11/16/2005	TAB	NET 30 DAYS. FINANCE CHARGE OF 1 1/2% PER MONTH, 18% PER YEAR ON ACCOUNTS OVER 30 DAYS.	none		
ORDERED	UNIT	BACK Q.	CATALOG NO. & DESCRIPTION	SHIPPED	UNIT PRICE	AMOUNT
1	1 ea	0	MAB-005 Lot Number: LIQUID NITROGEN STORAGE per clone per year up to 6 vials <small>Call Lisa Sperry (610-389-1008)</small>	1	\$89.00	\$89.00
					SubTotal:	\$89.00
					Shipping:	\$0.00
					Packing:	\$0.00
					<b>TOTAL:</b>	<b>\$89.00</b>
<p>Dr. Kimbely Zimnick/MAB-303-18A/MONOCLONAL ANTIBODY PRODUCTION</p> <p>Ship Acct # FEDX 1649-7065-S</p>						

Exhibit B



# THERION B I O L O G I C S

February 16, 2007

Celia Witten, M.D., Ph.D., Director  
Office of Cellular, Tissue and Gene Therapies  
CBER/FDA  
Document Control Room (HFM-99)  
Woodmont Building, Suite 200 North  
1401 Rockville Pike  
Rockville, MD 20852-1448

RE: Notification of Change in Sponsorship

Dear Dr. Witten:

This correspondence and the attached signed FDA 1571 Forms serve as notification of the change in sponsorship for the following INDs and Master Files, listed with the associated serial/amendment numbers for this submission:

BB-IND	10428	PROSTVAC-VF	Serial	0076
	10789	rV/rF-CEA(6D)/TRICOM + rV-MUC-1		0015
	11139	PANVAC-VF		0163
BB-MF	5029	TBC-CEA	Amendment	9
	5537	PROSTVAC		8
	6587	TBC-CEA		10
	6670	PROSTVAC		8
	7421	rF-PSA		8
	7468	rF-B7.1		8
	7646	PROSTVAC		8
	7733	rV-B7.1		7
	7860	rV-MUC-1		10
	7943	rF-gp100P209		9
	8022	rF-TYR		7
	8167	rV-TYR		7

Exhibit B.1 of 8

BB-MF			Amendment
	8570	rV-TRICOM	8
	8666	rF-GM-CSF	8
	8740	rV-CEA(6D)/TRICOM	9
	8863	rF-CEA(6D)/TRICOM	7
	8934	rF-TRICOM	7
	10837	TBC-FPV	6
	11094	TBC-Wy	5

Effective February 16, 2007, the new sponsor is the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute. The new sponsor contact is:

Jan M. Casadei, Ph.D.  
Associate Chief, Regulatory Affairs Branch  
Cancer Therapy Evaluation Program  
Division of Cancer Treatment and Diagnosis, NCI  
Executive Plaza North, Suite 7111  
6130 Executive Boulevard, MSC 7428  
National Institutes of Health, DCTD, NCI  
Bethesda, MD 20892-7428

All rights and responsibilities as well as regulatory documentation associated with these submissions have been transferred to the DCTD. Since all Therion-sponsored clinical studies conducted under the INDs listed above have been discontinued, the DCTD intends to convert these INDs to Type II Master Files, which will provide continued support for the related DCTD-sponsored INDs on these vaccine products. This will be further explained in the subsequent sponsorship acceptance communication from DCTD.

If you have any questions, I can be reached at 978-697-5486.

Sincerely,

  
Michael Wyand, DVM, Ph.D.  
President & CEO

<p style="text-align: center;">DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION</p> <p style="text-align: center;"><b>INVESTIGATIONAL NEW DRUG APPLICATION (IND)</b> (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)</p>		<p>Form Approved: OMB No. 0910-0014. Expiration Date: May 31, 2009 See OMB Statement on Reverse.</p> <p>NOTE: No drug may be shipped or clinical investigation begun until an IND for that investigation is in effect (21 CFR 312.40).</p>
1. NAME OF SPONSOR Therion Biologics Corporation	2. DATE OF SUBMISSION 02/16/2007	
3. ADDRESS (Number, Street, City, State and Zip Code) 76 Rogers Street Cambridge, MA 02142	4. TELEPHONE NUMBER (Include Area Code) 617-475-7500	
5. NAME(S) OF DRUG (include all available names: Trade, Generic, Chemical, Code) PROSTVAC-VF (PROSTVAC-V + PROSTVAC-F) PROSTVAC-VF/TRICOM (PROSTVAC-V/TRICOM+PROSTVAC-F/TRICOM)	6. IND NUMBER (If previously assigned) BB-IND 10428	
7. INDICATION(S) (Covered by this submission) Prostate Cancer		
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input type="checkbox"/> PHASE 1 <input checked="" type="checkbox"/> PHASE 2 <input type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER _____ (Specify)		
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. BB-IND 7718, 8397, 9306, 6960, 6698*, 8202, 5041*, 5571*, 6651*, 6796, 6897*, 6909, 8267, 8375, 8397, 8066 (* withdrawn) BB-MF 6587, 5537, 6670, 7646, 8570, 8740, 6698, 4910)		
10. IND submission should be consecutively numbered. The initial IND should be numbered "Serial number: 0000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 0001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER <u>0</u> <u>0</u> <u>7</u> <u>6</u>
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply)		
<input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) <span style="margin-left: 200px;"><input type="checkbox"/> RESPONSE TO CLINICAL HOLD</span>		
PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR <input type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION <input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVATED, TERMINATED OR DISCONTINUED	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL <input type="checkbox"/> ANNUAL REPORT <input checked="" type="checkbox"/> OTHER Notification of change in sponsorship (Specify)	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE
CHECK ONLY IF APPLICABLE		
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR SECTION FOR FURTHER INFORMATION.		
<input type="checkbox"/> TREATMENT IND 21 CFR 312.35(b) <input type="checkbox"/> TREATMENT PROTOCOL 21 CFR 312.35(a) <input type="checkbox"/> CHARGE REQUEST/NOTIFICATION 21 CFR 312.7(d)		
FOR FDA USE ONLY		
CDR/DBIND/DGD RECEIPT STAMP	DDR RECEIPT STAMP	DIVISION ASSIGNMENT:
		IND NUMBER ASSIGNED:

Exhibit B 3 of 8



12.

**CONTENTS OF APPLICATION**

This application contains the following items: (Check all that apply)

1. Form FDA 1571 [21 CFR 312.23(a)(1)]
2. Table of Contents [21 CFR 312.23(a)(2)]
3. Introductory statement [21 CFR 312.23(a)(3)]
4. General Investigational plan [21 CFR 312.23(a)(3)]
5. Investigator's brochure [21 CFR 312.23(a)(5)]
6. Protocol(s) [21 CFR 312.23(a)(6)]
- a. Study protocol(s) [21 CFR 312.23(a)(6)]
- b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)]
- Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)]
8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]
9. Previous human experience [21 CFR 312.23(a)(9)]
10. Additional information [21 CFR 312.23(a)(10)]

13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION?  YES  NO
- IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION?  YES  NO
- IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.

14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS
- Thomas Schuetz, MD, Ph.D.  
Chief Medical Officer


15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG
- Thomas Schuetz, MD, Ph.D.  
Chief Medical Officer

I agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set forth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.

16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE

Michael Wyand, DVM, Ph.D.  
President & CEO

17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE



18. ADDRESS (Number, Street, City, State and Zip Code)

76 Rogers Street  
Cambridge, MA 02142

19. TELEPHONE NUMBER (Include Area Code)

978-697-5486

20. DATE

02/16/2007

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)

Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Central Document Room  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research (HFM-99)  
1401 Rockville Pike  
Rockville, MD 20852-1448

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number."

Please DO NOT RETURN this application to this address.

Exhibit B 4 of 8

<b>DEPARTMENT OF HEALTH AND HUMAN SERVICES</b> <b>FOOD AND DRUG ADMINISTRATION</b>		Form Approved: OMB No. 0910-0014. Expiration Date: May 31, 2009 See OMB Statement on Reverse.
<b>INVESTIGATIONAL NEW DRUG APPLICATION (IND)</b> <b>(TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)</b>		NOTE: No drug may be shipped or clinical investigation begun until an IND for that investigation is in effect (21 CFR 312.40).
1. NAME OF SPONSOR Therion Biologics Corporation	2. DATE OF SUBMISSION 02/16/2007	
3. ADDRESS (Number, Street, City, State and Zip Code) 76 Rogers Street Cambridge, MA 02142	4. TELEPHONE NUMBER (Include Area Code) 617-475-7500	
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) PANVAC-VF	6. IND NUMBER (If previously assigned) BB-IND 11139	
7. INDICATION(S) (Covered by this submission) Adenocarcinoma of the Pancreas		
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input type="checkbox"/> PHASE 1 <input type="checkbox"/> PHASE 2 <input checked="" type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER _____ <span style="float: right;">(Specify)</span>		
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. BB-MF 8740, 7860, 8863 BB-IND 10789, 9306, 8066, 7718, 8202, 6909, 8267, 8375, 8397, 9888, 9710, 6960*, 5042*, 5571*, 6651*, 6796*, 6897*, 6698* (*withdrawn)		
10. IND submission should be consecutively numbered. The initial IND should be numbered "Serial number: 0000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 0001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER <u>0</u> <u>1</u> <u>6</u> <u>3</u>
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply)		
<input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) <input type="checkbox"/> RESPONSE TO CLINICAL HOLD		
PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR <input type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION <input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVATED, TERMINATED OR DISCONTINUED	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL <input type="checkbox"/> ANNUAL REPORT <input checked="" type="checkbox"/> OTHER <u>Notification of change in sponsorship</u> <span style="float: right;">(Specify)</span>	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE
<b>CHECK ONLY IF APPLICABLE</b>		
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR SECTION FOR FURTHER INFORMATION.		
<input type="checkbox"/> TREATMENT IND 21 CFR 312.35(b) <input type="checkbox"/> TREATMENT PROTOCOL 21 CFR 312.35(a) <input type="checkbox"/> CHARGE REQUEST/NOTIFICATION 21 CFR 312.7(d)		
<b>FOR FDA USE ONLY</b>		
CDR/DBIND/DGD RECEIPT STAMP	DDR RECEIPT STAMP	DIVISION ASSIGNMENT:
		IND NUMBER ASSIGNED:

12.

**CONTENTS OF APPLICATION**

This application contains the following items: (Check all that apply)

1. Form FDA 1571 [21 CFR 312.23(a)(1)]
2. Table of Contents [21 CFR 312.23(a)(2)]
3. Introductory statement [21 CFR 312.23(a)(3)]
4. General Investigational plan [21 CFR 312.23(a)(3)]
5. Investigator's brochure [21 CFR 312.23(a)(5)]
6. Protocol(s) [21 CFR 312.23(a)(6)]
- a. Study protocol(s) [21 CFR 312.23(a)(6)]
- b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)]
- Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)]
8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]
9. Previous human experience [21 CFR 312.23(a)(9)]
10. Additional information [21 CFR 312.23(a)(10)]

13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION?  YES  NO
- IF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION?  YES  NO
- IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.


14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS
- Thomas Schuetz, MD, Ph.D.  
Chief Medical Officer

15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG
- Thomas Schuetz, MD, Ph.D.  
Chief Medical Officer

I agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set forth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.

16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE
- Michael Wyand, DVM, Ph.D.  
President & CEO

17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE



18. ADDRESS (Number, Street, City, State and Zip Code)
- 76 Rogers Street  
Cambridge, MA 02142

19. TELEPHONE NUMBER (Include Area Code)
- 978-697-5486

20. DATE
- 02/6/2007

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)

Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Central Document Room  
5901-B Amundson Road  
Beltsville, MD 20705-1266

Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research (HFM-99)  
1401 Rockville Pike  
Rockville, MD 20852-1448

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number."

Please DO NOT RETURN this application to this address.

Exhibit B 6 of 8

DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION <b>INVESTIGATIONAL NEW DRUG APPLICATION (IND)</b> (TITLE 21, CODE OF FEDERAL REGULATIONS (CFR) PART 312)		Form Approved: OMB No. 0910-0014. Expiration Date: January 31, 2006 See OMB Statement on Reverse.
1. NAME OF SPONSOR Therion Biologics Corporation		2. DATE OF SUBMISSION 02/16/07
3. ADDRESS (Number, Street, City, State and Zip Code) 76 Rogers Street Cambridge, MA 02142		4. TELEPHONE NUMBER (Include Area Code) 617-475-7500
5. NAME(S) OF DRUG (Include all available names: Trade, Generic, Chemical, Code) rV-CEA (6D)/TRICOM™, rV-MUC-1, rF-CEA (6D)/TRICOM™		6. IND NUMBER (If previously assigned) BB-IND 10789
7. INDICATION(S) (Covered by this submission) Adenocarcinoma of the Pancreas		
8. PHASE(S) OF CLINICAL INVESTIGATION TO BE CONDUCTED: <input checked="" type="checkbox"/> PHASE 1 <input type="checkbox"/> PHASE 2 <input type="checkbox"/> PHASE 3 <input type="checkbox"/> OTHER _____ (Specify)		
9. LIST NUMBERS OF ALL INVESTIGATIONAL NEW DRUG APPLICATIONS (21 CFR Part 312), NEW DRUG OR ANTIBIOTIC APPLICATIONS (21 CFR Part 314), DRUG MASTER FILES (21 CFR Part 314.420), AND PRODUCT LICENSE APPLICATIONS (21 CFR Part 601) REFERRED TO IN THIS APPLICATION. BB-MF 8740, 7860, 8853 BB-IND 9306, 8066, 6960, 7718, 8202, 6909, 8267, 8375, 8397, 9888, 9710, 5042*, 5571*, 6651*, 6796*, 6897*, 6698* (*withdrawn)		
10. IND submission should be consecutively numbered. The Initial IND should be numbered "Serial number: 0000." The next submission (e.g., amendment, report, or correspondence) should be numbered "Serial Number: 0001." Subsequent submissions should be numbered consecutively in the order in which they are submitted.		SERIAL NUMBER <u>0</u> <u>0</u> <u>1</u> <u>5</u>
11. THIS SUBMISSION CONTAINS THE FOLLOWING: (Check all that apply)		
<input type="checkbox"/> INITIAL INVESTIGATIONAL NEW DRUG APPLICATION (IND) <input type="checkbox"/> RESPONSE TO CLINICAL HOLD		
PROTOCOL AMENDMENT(S): <input type="checkbox"/> NEW PROTOCOL <input type="checkbox"/> CHANGE IN PROTOCOL <input type="checkbox"/> NEW INVESTIGATOR <input type="checkbox"/> RESPONSE TO FDA REQUEST FOR INFORMATION <input type="checkbox"/> REQUEST FOR REINSTATEMENT OF IND THAT IS WITHDRAWN, INACTIVATED, TERMINATED OR DISCONTINUED	INFORMATION AMENDMENT(S): <input type="checkbox"/> CHEMISTRY/MICROBIOLOGY <input type="checkbox"/> PHARMACOLOGY/TOXICOLOGY <input type="checkbox"/> CLINICAL <input type="checkbox"/> ANNUAL REPORT <input checked="" type="checkbox"/> OTHER <u>Change in sponsorship</u> (Specify)	IND SAFETY REPORT(S): <input type="checkbox"/> INITIAL WRITTEN REPORT <input type="checkbox"/> FOLLOW-UP TO A WRITTEN REPORT <input type="checkbox"/> GENERAL CORRESPONDENCE
CHECK ONLY IF APPLICABLE		
JUSTIFICATION STATEMENT MUST BE SUBMITTED WITH APPLICATION FOR ANY CHECKED BELOW. REFER TO THE CITED CFR SECTION FOR FURTHER INFORMATION.		
<input type="checkbox"/> TREATMENT IND 21 CFR 312.35(b) <input type="checkbox"/> TREATMENT PROTOCOL 21 CFR 312.35(a) <input type="checkbox"/> CHARGE REQUEST/NOTIFICATION 21 CFR 312.7(d)		
FOR FDA USE ONLY		
CDR/DBIND/DGO RECEIPT STAMP	DDR RECEIPT STAMP	DIVISION ASSIGNMENT:
		IND NUMBER ASSIGNED:

12.

**CONTENTS OF APPLICATION**This application contains the following items: *(Check all that apply)*

1. Form FDA 1571 [21 CFR 312.23(a)(1)]
2. Table of Contents [21 CFR 312.23(a)(2)]
3. Introductory statement [21 CFR 312.23(a)(3)]
4. General Investigational plan [21 CFR 312.23(a)(3)]
5. Investigator's brochure [21 CFR 312.23(a)(5)]
6. Protocol(s) [21 CFR 312.23(a)(6)]
- a. Study protocol(s) [21 CFR 312.23(a)(6)]
- b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- c. Facilities data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
- d. Institutional Review Board data [21 CFR 312.23(a)(6)(iii)(b)] or completed Form(s) FDA 1572
7. Chemistry, manufacturing, and control data [21 CFR 312.23(a)(7)]
- Environmental assessment or claim for exclusion [21 CFR 312.23(a)(7)(iv)(e)]
8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)]
9. Previous human experience [21 CFR 312.23(a)(9)]
10. Additional information [21 CFR 312.23(a)(10)]

13. IS ANY PART OF THE CLINICAL STUDY TO BE CONDUCTED BY A CONTRACT RESEARCH ORGANIZATION?  YES  NOIF YES, WILL ANY SPONSOR OBLIGATIONS BE TRANSFERRED TO THE CONTRACT RESEARCH ORGANIZATION?  YES  NO

IF YES, ATTACH A STATEMENT CONTAINING THE NAME AND ADDRESS OF THE CONTRACT RESEARCH ORGANIZATION, IDENTIFICATION OF THE CLINICAL STUDY, AND A LISTING OF THE OBLIGATIONS TRANSFERRED.

14. NAME AND TITLE OF THE PERSON RESPONSIBLE FOR MONITORING THE CONDUCT AND PROGRESS OF THE CLINICAL INVESTIGATIONS

Thomas Schuetz, MD, PhD  
Chief Medical Officer

15. NAME(S) AND TITLE(S) OF THE PERSON(S) RESPONSIBLE FOR REVIEW AND EVALUATION OF INFORMATION RELEVANT TO THE SAFETY OF THE DRUG


Thomas Schuetz, MD, PhD  
Chief Medical Officer

I agree not to begin clinical investigations until 30 days after FDA's receipt of the IND unless I receive earlier notification by FDA that the studies may begin. I also agree not to begin or continue clinical investigations covered by the IND if those studies are placed on clinical hold. I agree that an Institutional Review Board (IRB) that complies with the requirements set forth in 21 CFR Part 56 will be responsible for initial and continuing review and approval of each of the studies in the proposed clinical investigation. I agree to conduct the investigation in accordance with all other applicable regulatory requirements.

16. NAME OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE

Michael Wyand, DVM, Ph.D  
President & CEO

17. SIGNATURE OF SPONSOR OR SPONSOR'S AUTHORIZED REPRESENTATIVE



18. ADDRESS (Number, Street, City, State and Zip Code)

76 Rogers Street  
Cambridge, MA 02142

19. TELEPHONE NUMBER (Include Area Code)

978-697-5486

20. DATE

02/16/07

**(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.)**

Public reporting burden for this collection of information is estimated to average 100 hours per response, including the time for reviewing instructions; searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration  
CBER (HFM-99)  
1401 Rockville Pike  
Rockville, MD 20852-1448

Food and Drug Administration  
CDER (HFD-94)  
12229 Wilkins Avenue  
Rockville, MD 20852

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number."

Please DO NOT RETURN this application to this address.

Exhibit B 8 of 8

Exhibit C



# THERION

---

B I O L O G I C S

February 16, 2007

Iron Mountain  
1000 Campus Drive  
Collegeville, PA 19426

Fax: 1-800-934-5348

Re: Account Number 81955

To whom it may concern:

On behalf of Therion Biologics Corporation ("Therion"), I authorize Iron Mountain to transfer immediately the materials and/or documents stored at your facility by Therion to the National Cancer Institute, care of:

Dr. Jeffrey Schlom, Ph.D.  
Chief, Laboratory of Tumor Immunology and Biology  
Center for Cancer Research National Cancer Institute National Institutes of Health  
10 Center Drive, Bldg. 10, Rm. 8B09  
Bethesda, MD 20892  
(301) 496-4343  
Fax (301) 496-2756

Sincerely,

Michael S. Wyand, DVM, Ph.D.  
President and CEO


---

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
[www.therionbio.com](http://www.therionbio.com)

Exhibit C 1 of 3



# THERION

---

B I O L O G I C S

February 16, 2007

Fisher Bioservices, Inc.  
685 Lofstrand Lane  
Rockville, MD 20850

ATTN: Scott Hixon

To whom it may concern:

On behalf of Therion Biologics Corporation ("Therion"), I authorize Fisher Bioservices, Inc. to transfer immediately the materials and/or documents stored at your facility by Therion to the National Cancer Institute, care of:

Dr. Jeffrey Schlom, Ph.D.  
Chief, Laboratory of Tumor Immunology and Biology  
Center for Cancer Research National Cancer Institute National Institutes of Health  
10 Center Drive, Bldg. 10, Rm. 8B09  
Bethesda, MD 20892  
(301) 496-4343  
Fax (301) 496-2756

Sincerely,

Michael S. Wyand, DVM, Ph.D.  
President and CEO

---

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
[www.therionbio.com](http://www.therionbio.com)

Exhibit C 2 of 3





# THERION

---

B I O L O G I C S

February 16, 2007

Rockland Immunochemicals, Inc.  
P.O. Box 326  
Gilbertville, PA 19525

ATTN: Tabby Eckert

To whom it may concern:

On behalf of Therion Biologics Corporation ("Therion"), I authorize Rockland Immunochemicals, Inc. to transfer immediately the materials and/or documents stored at your facility by Therion to the National Cancer Institute, care of:

Dr. Jeffrey Schlom, Ph.D.  
Chief, Laboratory of Tumor Immunology and Biology  
Center for Cancer Research National Cancer Institute National Institutes of Health  
10 Center Drive, Bldg. 10, Rm. 8B09  
Bethesda, MD 20892  
(301) 496-4343  
Fax (301) 496-2756

Sincerely,

Michael S. Wyand, DVM, Ph.D.  
President and CEO

---

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
[www.therionbio.com](http://www.therionbio.com)

Exhibit C 3 of 3

Exhibit D

**PATENT**

Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-673 1

**ASSIGNMENT**

**WHEREAS**, Therion Biologics Corp. of 222 Third Street, Suite 2300, Cambridge, Massachusetts, 02142 USA (hereinafter referred to as Assignor), co-owns certain inventions for which patent applications were executed for patents, as identified in the Attachment hereto, and

**WHEREAS**, the Government of the United States of America (hereinafter referred to as Assignee) is desirous of acquiring the Assignor's right, title, and interest in and under the inventions described in the patent applications identified in the Attachment hereto or otherwise co-owned with an employee of the United States.

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to the Assignee, represented by the Secretary, Department of Health and Human Services, the full and exclusive rights, title, and interest in and to (a) the patents, patent applications, and inventions identified in the Attachment hereto, or otherwise co-owned with an employee of the United States, whether filed in the United States or elsewhere (e.g., in any region or country of the world), (b) other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, PCT applications, national phase applications, petty patent applications, and utility model applications) that may be filed in the United States or elsewhere (e.g., in any region or country of the world) on the inventions identified in the Attachment hereto and/or that claim priority to any of the patents and patent applications identified in the Attachment hereto, and (c) the patents, extensions, or derivations thereof that may issue on or from any of the aforementioned patents and patent applications.

**ASSIGNOR HEREBY AUTHORIZES** and requests the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee agreeably with the terms of this assignment document.

**ASSIGNOR ALSO HEREBY AUTHORIZES** the Assignee to insert into this assignment document (e.g., into the Attachment hereto) the filing date and application number of any patent application identified in the Attachment hereto or otherwise co-owned with an employee of the United States for which the filing date and particulars (e.g., patent number and/or patent application number) are unavailable at the time this assignment document is executed.

**UPON SAID CONSIDERATION**, Assignor conveys to the Assignee the right to make application in its own behalf for protection of the invention in the U.S. and elsewhere (i.e., in any countries) and to claim under the Patent Cooperation Treaty, the International Convention, and/or other international arrangement for any such patent application the date of the U.S. application (or any other patent application on the invention) to gain priority with respect to other patent applications.

**ASSIGNOR DOES HEREBY COVENANT** and agree with the Assignee that it will not execute any writing or do any act whatsoever conflicting with the terms of this assignment document set forth herein, and that Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee and subject to the terms of this Settlement Agreement, execute such

additional assignments and other writings as may be necessary to perfect the Assignee's enjoyment of this assignment, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, the undersigned has set his hand on the date shown below.

Date 2/27/07

Michael S. Wyand

Signature of Authorized Officer  
Therion Biologics Corp.

Michael S. Wyand

Printed Name of Authorized Officer  
Therion Biologics Corp.

President CEO

Title of Authorized Officer  
Therion Biologics Corp.

STATE OF MA

COUNTY OF Middlesex

On this 27 day of Feb, 2007, before me, a Notary Public in and for said county, appeared \_\_\_\_\_, who is personally known to me to be the same person whose name is subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

(SEAL)

100159939\_1.DOC

PREMA K MATTHEWS

Notary Public

My commission

Expires: June 16, 2011



**PREMA K MATTHEWS**  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires June 16, 2011

THERION CASE LIST - JOINTLY OWNED		I.C. /CO-OWNED					
Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref No.	NY Matter No.	I.C. /CO-OWNED
10/660,569	9/11/2003	TRANSFUSED NEOPLASTICE CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY .....	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006 per NIH request INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/20 CONVEYED TO AND CONFIRMED BY E&A ON 12/04/2006	12/20/2006		054440-US	NIH
50884498	7/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action or Request for Extension	1/3/2007	TBC-1025-JP	046570-JP	NIH
11135175	6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PAS)	Response to Office Action or Request for Extension	1/17/2007	TBC-1022	045394-EP DIV	NIH
2282,300	2/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action	1/17/2007	FO27/CA	047113-CA	NIH
10/197,127	07/17/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to non-final Office Action	2/2/2007	TBC-1025	046570-CFA2C-US	NIH
2006-532294	2/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	P003JP	053627-JP	NIH
4811370.8	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Registration in HK	2/9/2007	P004PCT	053674-EP	NIH
08/296,385 6,001,349	02/22/1995 12/14/1999	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	06/14/2007 (12/14/1007) EXPIRES 12/14/2016	POJO US	044933-US	NIH JH
09/287,221 6,319,496	4/06/1999 11/20/2001	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	05/20/2009 (11/20/2009) EXPIRES 02/25/2015	POJO US	044933-US	NIH
5024096	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (08/13/2007)	POJO AI	044933-AU	NIH I

2,213,451	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 02/13/2008	POJO CA	044933-CA	NIH
9690706 1.4	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/28/2007 (08/28/2007)	POJO EP	044933-EP	NIH
H08-525,765	2/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	TRANSFERRED TO E&A ON(1/02/2006 PER NIH REQUEST		POJO IP	044933-JP	NIH
08/500,306 6,165,460	07/10/1995	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	8th year Maintenance Fee	06/26/2007 (12/26/2008) EXPIRES 07/10/2015	P030	045394-US	NIH
09/693,121	1/02/2000	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Appeal brief	04/21/2007	P030	045394-CPA.2 C-	NIH
2,226,436 ISSUED	06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (06/26/2008)	US P030 CA	US 045394-CA	NIH
696,1860 1.2 ISSUED	06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 DE	045394-DE	NIH
969234 1.7.8	06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 EP	0-15394-EP	NIH
1113517.5	6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PSA)	Response to Office Action	1/17/2007	P030 EP- DV	045394-EP DIV	NIH
2103565.7	8/16/2002	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	6/26/2008	P030 HK	045394-1-HK	NLH
9-505834	06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	SEQUENCE LISTING WAS DUE 11/10/2006		P030 JP- DV	045394-JP-DIV	NIH
2006-3 868 1	2/15/2006	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	WAITING FOR RESPONSE FROM JPO - RESPONSETOOA WAS FILED FEBRUARY 2006		P030 JP	045394- JP	NIH
10/197,127	07/17/2002	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to non-final Office Action	02/02/2007	P01 1 US	046570-CFA2C-US	NIH

2003266471	11/27/2003	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007	(01/15/2008)	P011 AU-DV-2	046570-AU-DIV 2	NIH
3726897 ISSUED	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007	(01/15/2008)	P011 AU-DV	046570-AU-DIV	NIH
5419401	07/04/2001	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007	(01/15/2008)	P011 CA	046570-CA	NIH
2.261.989	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007	(01/15/2008)	P011 EP	046570-EP	NIH
97934142.7	07/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007	(01/15/2008)	P011 EP	046570-EP	NIH
50884498	7/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to Office Action	01/03/2007	(04/03/2007, if request is made by 01/03/2007)	P011 JP	046570-JP	NIH
10057136 ISSUED 7, 118,738	1/25/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	4 <sup>th</sup> year Maintenance Fee	04/12/2010	(10/12/2010) EXPIRES	P027 US	047113-US	NIH
6186098	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax payment	02/24/2007	(08/24/2007)	P027 AU	047113-AU	NIH
2282300	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Response to Office Action Tax payment 1	01/17/2007	(02/24/2008)	P027 CA	047113-CA	NIH
98906706.1	02/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax Payment	2/24/707	(08/24/2007)	P027 EP	047113-EP	NIH
10660369	09/11/2003	TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006	12/20/2006		P037 US STA (NFC)	054440-US	NIH STANFORD
08238611 ISSUED 5,656,465	05/04/1994 08/12/1997	METHODS OF IN VIVO GENE DELIVERY	12 <sup>th</sup> Year Maintenance Fee	02/12/2009	(08/12/2009) EXPIRES	P024 US	042777-US	NIH
2543795	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007	(11/03/2007)	P024 AU	042777-AU	NIH

2,189,452	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax Payment	05/03/20(17 (05/03/2008)	P024 CA	042777-CA	NIH
95919744.3	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax Payment	05/03/2007 (11/03/2007)	P024 EP	042777-EP	NIH
08270,106 ISSUED 5,698,530	7/1/1994	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	12 <sup>th</sup> year Maintenance Fee	06/16/2009 (12/16/2009)	P002 US	045773- US	NIH
2006092	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax Payment	05/06/2007 (11/06/2007)	P002 AU	046773-AU	NIH
2,102,623	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax Payment	05/06/2007 (05/06/2008)	P002 CA	046773 CA	NIH
92913153.0 ISSUED UK, SE ML, MC, CH, LU, DE, DK, FI, ES FR, GR, IT, BE, AT	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax Payment	05/06/2007 (11/06/2007) EXPIRES 11/06/2012	P002 EP	046773-EP	NIH
4-512025	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	05/06/2007 (11/06/2007)	P0021 P	046773- JP	NIH
10,543,944	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Waiting for 1 <sup>st</sup> OA	-	P003 US	053622- US	NIH
2004291024	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment and Request for Examination	02/20/1009 (08/20/2009)	P003 AU	053623-AU	NIH
2,515,890	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment Request for Examination	02/20/2007 (02/20/2008)	P003 CA	053624-CA	NIH
4,817,690	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment	02/28/2007 (08/28/2007)	P003 EP	053626-EP	NIH
2006-532294	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	P0031 P	053627-JP	NIH
10,579,007	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Waiting for 1 <sup>st</sup> OA	-	P005US	05366 6- US	NIH
2004289340	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment (05/12/2010)	11/12/2009	P005 AU 2- AU	5366	NIH
4810831	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment	11/30/2006 (05/30/2007)	P005EP	05366 3- EP	NIH
2,545,164	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Assignment due	05/05/2007	P005CA	05366 4- CA	NIH
2006-539904	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Request for Examination	11/12/2007	P005 JP	05366 5-JP	NIH
10,579,025	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Waiting for 1 <sup>st</sup> OA	-	P004US	05367 6- US	NIH



Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
2004289368	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Tax payment and Request for Examination	11/12/2009	P004AU	053 67 2- AU	NIH
TBA	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Assignment due Tax payment Request for Examination	05/05/2007 11/12/2007 11/12/2008 11/12/2009	P004CA	053673-CA.11	NIH
4811370.8	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Registration in HK Tax payment	02/09/2007 11/30/2006 (05/30/2007)	P004EP	053674-EP	NIH
TBA	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Request for Examination	11/12/2007	P004P	5367	NIH
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-200-1990/4-EIR-00	00/00/00	00/00/00	E-200-1990/4-EIR-00	08/500,306	EIR		00/00/00
E-200-1990/4-US-01	08/500,306	07/10/1995	E-200-1990/4-US-01	08/500,306	ORD	6,165,460	12/26/00
E-200-1990/4-PCT-02	PCT/US96/10837	06/26/1996	E-200-1990/4-PCT-02	08/500,306	PCT		00/00/00
E-200-1990/4-CA-03	2228436	06/26/1996	E-200-1990/4-CA-03	08/500,306	PCT		00/00/00
E-200-1990/4-EP-04	96923417.8	06/26/1996	E-200-1990/4-EP-04	08/500,306	PCT		00/00/00
E-200-1990/4-JP-05	9-505834	06/26/1996	E-200-1990/4-JP-05	08/500,306	PCT		00/00/00
E-200-1990/4-US-06	09/693,121	10/20/00	E-200-1990/4-US-06	08/500,306	CON		00/00/00
E-200-1990/4-EP-07	1113517.5	06/26/1996	E-200-1990/4-EP-04	08/500,306	DIV		00/00/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-119-1994/0-EIR-00	00/00/00	00/00/00	E-119-1994/0-EIR-00	08/238,611	EIR		00/00/00
E-119-1994/0-US-01	08/238,611	05/04/1994	E-119-1994/0-US-01	08/238,611	ORD	5,656,465	08/12/1997
E-119-1994/0-PCT-02	PCT/JU95/05487	05/03/1995	E-119-1994/0-PCT-02	08/238,611	PCT		00/00/00
E-119-1994/0-AU-03	2543795	05/03/1995	E-119-1994/0-PCT-02	08/238,611	PCT	716959	06/22/00
E-119-1994/0-CA-04	2189452	05/03/1995	E-119-1994/0-PCT-02	08/238,611	PCT		00/00/00
E-119-1994/0-JP-05	07-692062	05/03/1995	E-119-1994/0-PCT-02	08/238,611	PCT		00/00/00
E-119-1994/0-EP-06	95919744.3	05/03/1995	E-119-1994/0-PCT-02	08/238,611	PCT		00/00/00
E-119-1994/0-JP-07	2003-333086	05/03/1995	E-119-1994/0-JP-05	08/238,611	DIV		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/2-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/2-PCT-01	PCT/US95/12638	10/02/1995	E-259-1994/0-US-01	08/317,402	PCT-COMB		00/00/00
E-259-1994/2-CA-02	2201592	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT		00/00/00
E-259-1994/2-AU-03	39982/95	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT	712714	02/24/00
E-259-1994/2-EP-04	95938706.9	10/02/1995	E-259-1994/2-PCT-01	08/317,402	PCT		00/00/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/3-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/3-US-01	08/686,280	07/25/1996	E-259-1994/3-EIR-00	08/686,280	ORD		00/00/00
E-259-1994/3-PCT-02	PCT/US97/12203	07/15/1997	E-259-1994/3-US-01	08/686,280	PCT		00/00/00
E-259-1994/3-CA-03	2261989	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00
E-259-1994/3-EP-04	97934142.7	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00
E-259-1994/3-JP-05	508844/98	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT		00/00/00
E-259-1994/3-AU-06	37268/97	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT	731860	04/05/01
E-259-1994/3-AU-07	54194/01	07/15/1997	E-259-1994/3-PCT-02	08/686,280	PCT	767562	11/13/03
E-259-1994/3-US-08	10/197,127	07/17/02	E-259-1994/3-US-01	08/686,280	CON		00/00/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-259-1994/4-EIR-00		00/00/00			EIR		00/00/00
E-259-1994/4-US-01	08/686,281	07/25/1996	E-259-1994/4-EIR-00	08/686,281	ORD		00/00/00
E-259-1994/4-PCT-02	PCT/US97/12546	07/09/1997	E-259-1994/4-US-01	08/686,281	PCT		00/00/00
E-259-1994/4-CA-03	2261990	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-EP-04	97933544.5	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-JP-05	36706/97	07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT		00/00/00
E-259-1994/4-AU-06		07/09/1997	E-259-1994/4-PCT-02	08/686,281	PCT	718945	08/17/00
Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-154-1998/0-EIR-00		00/00/00			EIR		00/00/00
E-154-1998/0-US-01	60/038,253	02/24/1998	E-154-1998/0-EIR-00	60/038,253	PRV		00/00/00
E-154-1998/0-PCT-02	PCT/US98/03693	02/24/1998	E-154-1998/0-US-01	60/038,253	PCT		00/00/00
E-154-1998/0-AU-03	61860/98	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT	727308	03/22/01
E-154-1998/0-CA-04	2282300	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT		00/00/00
E-154-1998/0-EP-05	98906706.1	02/24/1998	E-154-1998/0-PCT-02	60/038,253	PCT		00/00/00
E-154-1998/0-US-06	09/366,670	08/03/1999	E-154-1998/0-PCT-02	60/038,253	371		00/00/00
E-154-1998/0-US-07	10/057,136	01/25/02	E-154-1998/0-US-06	60/038,253	CON		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-256-1998/0-EIR-00	00/00/00	00/00/00			EIR		00/00/00
E-256-1998/0-US-01	60/111,582	12/09/1998	E-256-1 998/0-EIR-00	60/111,582	PRV		00/00/00
E-256-1998/0-PCT-02	PCT/US99/26866	11/12/1999	E-256-1 998/0-US-01	60/111,582	PCT		00/00/00
E-256-1998/0-AU-03	16218/00	11/12/1999	E-256-1 998/0-PCT-02	60/111,582	PCT	774076	05/05/05
E-256-1998/0-EP-04	99858951.8	11/12/1999	E-256-1 998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-JP-05	2000-586927	11/12/1999	E-256-1 998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-CA-06	2354024	11/12/1999	E-256-1 998/0-PCT-02	60/111,582	PCT		00/00/00
E-256-1998/0-US-07	09/856,988	09/24/01	E-256-1 998/0-PCT-02	60/111,582	371	6,969,609	11/29/05
E-256-1998/0-US-08	10/406,317	04/04/03	E-256-1 998/0-US-07	60/111,582	DIV		00/00/00
E-256-1 998/1 -EIR-00	00/00/00	00/00/00			EIR		00/00/00
E-256-1 998/1 -US-01	11/321,868	12/30/05	E-256-1 998/0-US-08	60/111,582	CIP		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-187-2000/0-EIR-00	00/00/00	00/00/00			EIR		00/00/00
E-187-2000/0-US-01	60/211,717	06/15/00	E-187-2000/0-EIR-00	60/211,717	PRV		00/00/00
E-187-2000/0-PCT-02	PCT/US01/19201	06/15/01	E-187-2000/0-US-01	60/211,717	PCT		00/00/00
E-187-2000/0-US-03	10/297,168	07/16/03	E-187-2000/0-PCT-02	60/211,717	371		00/00/00
E-187-2000/0-EP-04	1946395.9	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-CA-05	2412050	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-AU-06	2001268452	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-JP-07	2002-510097	06/15/01	E-187-2000/0-PCT-02	60/211,717	PCT		00/00/00
E-187-2000/0-HK-08	3105975.5	08/21/03	E-187-2000/0-EP-04	60/211,717	PCT		00/00/00

Reference Number	Application Number	Filing Date	Parent Reference Number	Priority Application #	Case Type	Patent Number	Issue Date
E-087-2005/0-EIR-00	00/00/00	00/00/00			EIR		00/00/00
E-087-2005/0-US-01	60/519,354	11/12/03	E-087-2005/0-EIR-00	60/519,354	PRV		00/00/00
E-087-2005/0-PCT-02	PCT/US2004/38643	11/12/04	E-087-2005/0-US-01	60/519,354	PCT		00/00/00
E-087-2005/0-US-03	10/578,025	05/11/06	E-087-2005/0-PCT-02	60/519,354	119		00/00/00
E-087-2005/0-AU-04	2004289368	11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-CA-05		11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-EP-06	4811370.8	11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-087-2005/0-JP-07		11/12/04	E-087-2005/0-PCT-02	60/519,354	PCT		00/00/00
E-088-2005/0-EIR-00	00/00/00	00/00/00			EIR		00/00/00
E-088-2005/0-US-01	60/519,427	11/12/03	E-088-2005/0-EIR-00	60/519,427	PRV		00/00/00
E-088-2005/0-PCT-02	PCT/US2004/03761 0	11/12/04	E-088-2005/0-US-01	60/519,427	PCT		00/00/00
E-088-2005/0-US-03	00/000,000	05/11/06	E-088-2005/0-PCT-02	60/519,427	119		00/00/00
E-088-2005/0-AU-04	2004289340	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00
E-088-2005/0-CA-05	2,545,164	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00
E-088-2005/0-EP-06	4810881	11/12/04	E-088-2005/0-PCT-02	60/519,427	PCT		00/00/00

E-028-2005/0-JP-07		11/12/04	E-028-2005/0-PCT-02	60/519,427	PCT	000/00/00
E-028-2007/0-EIR-00		00/00/00			EIR	000/00/00
E-028-2007/0-US-01	60/448,591	02/20/03	E-028-2007/0-EIR-00	60/448,591	PRV	000/00/00
E-028-2007/0-PCT-02	PCT/US2004/00507 7	02/20/04	E-028-2007/0-US-01	60/448,591	PCT	000/00/00
E-028-2007/0-JP-03		00/00/00	E-028-2007/0-PCT-02		PCT	000/00/00

E-320-2005/0-US-02	10/660,369	09/11/03	E-320-2005/0-US-01	60/410,161	111	000/00/00
--------------------	------------	----------	--------------------	------------	-----	-----------

[Redacted]

**Exhibit E**

POWER OF ATTORNEY

BE IT KNOWN, that Therion Biologics Corp. of 222 Third Street, Suite 2300, Cambridge, Massachusetts, 02142 USA (hereinafter referred to as Therion), has made and appointed, and by these presents does make and appoint, Dr. Mark Rohrbaugh, Director, NIH Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 or any designee, acting on behalf of the United States Department of Health & Human Services, true and lawful attorney for Therion and, in Therion's name, place, and stead, gives and grants to said attorney, general and full authority to do and perform each and every act and thing whatsoever requisite necessary to be done with respect to (a) the patents, patent applications, and inventions identified in the Attachment hereto, whether filed in the United States or elsewhere (e.g., in any region or country of the world), (b) other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, PCT applications, national phase applications, petty patent applications, and utility model applications) that may be filed in the United States or elsewhere (e.g., in any region or country of the world) on the inventions identified in the Attachment hereto and/or that claim priority to any of the patents and patent applications identified in the Attachment hereto, and (c) the patents, extensions, or derivations thereof that may issue on or from any of the aforementioned patents and patent applications, as could be done by Therion, with full power of substitution and revocation, and hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has set his hand on the date shown below.

Date 2/27/07

Michael S. Wyand

Signature of Authorized Officer  
Therion Biologics Corp.

Michael S. Wyand

Printed Name of Authorized Officer  
Therion Biologics Corp.

President + CEO

Title of Authorized Officer  
Therion Biologics Corp.

STATE OF MA )

COUNTY OF Middlesex )

On this 27 day of Feb, 2007, before me, a Notary Public in and for said county, appeared \_\_\_\_\_, who is personally known to me to be the same person whose name is subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

{SEAL}


PREMA K MATTHEWS

Notary Public  
**PREMA K MATTHEWS**  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires June 16, 2011

Exhibit E 1 of 6

Expires June 16, 2011

My Commission Expires: \_\_\_\_\_



Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref. No.	NI Matter No.	I.I.C. /CO-OWNED
10660,369	9/11/2003	TRANSFUSED NEOPLASTICE CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY.....	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006 per NIH request INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/30 CONVEYED TO AND CONFIRMED BY E&A ON 12/04/2006	12/20/2006		054440-US	NIH
508844/98	7/15/1997	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action or Request for Extension	1/3/2007	TBC-1025-JP	046570-JP	NIH
1113517.5	6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PSA)	Response to Office Action or Request for Extension	1/17/2007	TBC-1022	045394-EP DIV	NIH
2,282,300	2/24/1998	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action	1/17/2007	PO27CA	047113-CA	NIH
10197,127	07/17/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to non-final Office Action	2/2/2007	TBC-1025	046570-CPA2C-US	NIH
2006-532294	2/20/2004	NOVEL INSERTION SITES IN POX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	PO03JP	053627-JP	NIH
4811370.8	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Registration in HK	2/9/2007	PO04PCI	053674-EP	NIH
08296,385 6,001,349	ISSUED 02/22/1995	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	06/14/2007 (12/14/1007) EXPIRES 12/14/2016	PO10 US	044933-US	NIH
09287,221 6,319,496	ISSUED 4/06/1999	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	05/20/2009 (11/20/2009) EXPIRES 02/25/2015	PO10 US	044933-US	NIH
50240/96	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (08/13/2007)	PO10 AI	044933-AU	NIH



2,213,451		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (02/13/2008)	FOJO CA	044933-CA	NIH
9690706 1.4		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/28/2007 (08/28/2007)	FOJO EP	044933-EP	NIH
H08-523,765		2/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	TRANSFERRED TO E&A ON(11/02/2006 PER NIH REQUEST		FOJO IP	044933-IP	NIH
08/500,306 6,165,460	ISSUED	07/10/1995	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	8th year Maintenance Fee	06/26/2007 (12/26/2008) EXPIRES 07/10/2015	P030	045394-US	NIH
09/693,121		10/20/2000	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Appeal brief	04/21/2007	P030	045394-CPA.2 C-	NIH
2,226,436 ISSUED		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (06/26/2008)	US P030 CA	US 045394-CA	NIH
696 1860 1.2 ISSUED		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 DE	045394-DE	NIH
969234 1 7.8		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 EP	0-15394-EP	NIH
1113517.5		6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PSA)	Response to Office Action	1/17/2007	P030 EP-DV	045394-EP DIV	NIH
2103565.7		8/16/2002	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	6/26/2008	P030 HK	045394-EHK	NHL
9-505834		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	SEQUENCE LISTING WAS DUE 11/10/2006		P030 JP-DV	045394-JP-DIV	NIH
2006-3 868 1		2/15/2006	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	WAITING FOR RESPONSE FROM JPO - RESPONSETOOA WAS FILED FEBRUARY 2006		P030 JP	045394-JP	NIH
10/197,127		07/17/2002	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to non-final Office Action	02/02/2007	F01 1 US	046570-CPA2C-US	NIH

2003266471	11/27/2003	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV-2	046570-AU-DIV	NIH
3726897 ISSUED	07/15/1997	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV	046570-AU-DIV	NIH
5419401	07/04/2001	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV	046570-AU-DIV	NIH
2.261.989	07/15/1997	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 CA	046570-CA	NIH
97934142-7	07/15/1997	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 EP	046570-EP	NIH
50884498	7/15/1997	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to Office Action request is made by	01/03/2007 (04/03/2007, if request is made by 01/03/2007)	P011P	046570-CP	NIH
10057136 ISSUED 7, 118, 738	1/25/2002	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	4 <sup>th</sup> year Maintenance Fee	04/12/2010 (10/12/2010) EXPIRES	P027 US	047113-US	NIH
6186098	02/24/1998	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax payment	02/24/2007 (08/24/2007)	P027 AU	047113-AU	NIH
2.282.300	02/24/1998	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Response to Office Action Tax payment 1	01/17/2007 (02/24/2007)	P027 CA	047113-CA	NIH
98906706.1	02/24/1998	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax Payment	2/24/2007 (08/24/2007)	P027 EP	047113-EP	NIH
10660369	09/11/2003	TRANSFUSED NEOPLASMIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES BY T, ICAM-1, AND LEA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006	12/20/2006	P037 US STANFORD	054440-US	NIH STANFORD
08/238,611 ISSUED 5,636,465	05/04/1994 08/12/1997	METHODS OF IN VIVO GENE DELIVERY	INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/20 CONVEYED TO AND CONFERRED BY E&A ON 12/04/2006	02/12/2009 (08/12/2009) EXPIRES	RU REF. S02-036	042777-US	NIH
2543795	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007 (11/03/2007)	P024 AU	042777-AU	NIH

2,189,452	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007 (05/03/2008)	P024 CA	042777-CA	NIH
95919744.3	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment	05/03/2007 (11/03/2007)	P024 EP	042777-EP	NIH
08270,106 ISSUED 5,698,530	7/1/1994	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	12 <sup>th</sup> year Maintenance Fee	06/16/2009 (12/16/2009)	P002 US	045773-US	NIH
20060/92	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (11/06/2007)	P002 AU	046773-AU	NIH
2,102,623	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (05/06/2008)	P002 CA	046773-CA	NIH
92913153.0 ISSUED UK SE ML MC CH LU DE DK FI ES FR GR IT BE AT	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment	05/06/2007 (1/06/2007) EXPIRES 11/06/2012	P002 EP	046773-EP	NIH
4-512025	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	05/06/2007 (11/06/2007)	P002 P	046773-JP	NIH
10/543,944	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Waiting for 1 <sup>st</sup> OA	-	P003 US	053622-US	NTH
2004291024	02/20/2004	NO VEL INSERTION SITES EN FOX VECTORS	Tax Payment and Request for Examination	02/20/1009 (08/20/2009)	P003 AU	053623-AU	NIH
2,514,890	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment Request for Examination	02/20/2007 (02/20/2008)	P003 CA	053624-CA	NIH
4,817,690	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment	02/20/2009 (08/28/2007)	P003 EP	053626-EP	NIH
2006-532294	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	P003 P	053627-JP	NIH
10/579,007	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Waiting for 1st OA	-	P005 US	05366 6-US	NIH
2004289340	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment (05/12/2010)	11/12/2009	P005 AU 2-AU	5366	NIH
4810831	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment	11/30/2006 (05/30/2007)	P005 EP	05366 3-EP	NIH
2,545,164	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Assignment due	05/05/2007	P005 CA	05366 4-CA	NIH
2006-599904	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Request for Examination	11/12/2007	P005 JP	05366 5-JP	NIH
10/579,025	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Waiting for 1 <sup>st</sup> OA	-	P004 US	05367 6-US	NIH

Exhibit F



# THERION

---

B I O L O G I C S

Ronald I. Eisenstein  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110

February 16, 2007

Re: Transfer of Patent Files for National Institutes of Health (See Attachment)

Mr. Eisenstein,

Pursuant to the signed Power of Attorney and as instructed herewith, please transfer all files for the referenced cases in the Attachment to the following:

John Kilyk, Jr.  
Attorney at Law  
Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza - Suite 4900  
180 North Stetson Avenue  
Chicago, IL 60601-6731

Additionally, please file a Request to Withdraw as Attorney of Record in connection with the attached matters, changing the correspondence address to the above Leydig, Voit & Mayer, Ltd. address. Lastly, instruct all of your foreign associates to correspond directly with John Kilyk, Jr.

Please acknowledge safe transfer of the files by signing below and returning a copy of this letter to the following:

Michelle A. Booden, Ph.D.  
Office of Technology Transfer  
Cancer Branch  
National Institutes of Health  
6011 Executive Blvd., Rm 325  
Rockville, MD 20852

Very truly yours,

Michael Wyand, DVM, Ph.D.  
President and CEO  
Therion Biologics, Inc.

---

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
www.therionbio.com

Exhibit F 1 of 5

Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref. No.	NY Matter No.	1.C./CO-OWNED
10/660,369	9/11/2003	TRANSFUSED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY.....	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006 per NIH request INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/20 CONVEYED TO AND CONFIRMED BY E&A ON 12/04/2006	12/20/2006		054440-US	NIH
50884498	7/15/1997	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action or Request for Extension	1/3/2007	TBC-1025-JP	046570-JP	NIH
11133175	6/26/1996	GENERATION OF IMMUNE RESPONSE TO PROSTATE SPECIFIC ANTIGEN (PSA)	Response to Office Action or Request for Extension	1/17/2007	TBC-1022	045394-EF DIV	NIH
2,282,300	2/24/1998	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to Office Action	1/17/2007	PO27CA	047113-CA	NIH
10/197,127	07/17/2002	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR ASSOCIATED ANTIGENS	Response to non-final Office Action	2/2/2007	TBC-1025	046570-CFA2C-US	NIH
2006-532294	2/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST	2/20/2007	PO03JP	053627-JP	NIH
4811370.8	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Registration in HK	2/9/2007	PO04PCT	053674-EF	NIH
08/396,385 6,001,349	02/22/1995 12/14/1999	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	06/14/2007 (12/14/1007) EXPIRES 12/14/2016	FOIO US	044933-US	NIH
09287,221 6,319,496	4/06/1999 11/20/2001	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	8th Year Maintenance Fee	05/20/2009 (11/20/2009) EXPIRES 02/25/2015	FOIO US	044933-US	NIH
5024096	02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (08/13/2007)	POIO AI	044933-AU	NIH

2,213,451		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/13/2007 (02/13/2008)	FOIO CA	044933-CA	NIH
9690706 1.4		02/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	Tax payment	02/28/2007 (08/28/2007)	FOIO EP	044933-EP	NIH
E08-525,765		2/13/1996	GENERATION OF HUMAN CYTOTOXIC T-CELLS SPECIFIC FOR CARCINOMA SELF-ASSOCIATED ANTIGENS AND USES THEREOF	TRANSFERRED TO E&A ON(1/02/2006 PER NIH REQUEST		FOIO IP	044933-JP	NIH
08/500,306 6,165,460	ISSUED	07/10/1995	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	8th. year Maintenance Fee	06/26/2007 (12/26/2008) EXPIRES 07/10/2015	P030	045394-US	NIH
09/693,121		1 0/20/2000	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Appeal brief	04/21/2007	P030	045394-CPA.2 C.	NIH
2,226,436 ISSUED		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (06/26/2008)	US P030 CA	US 045394-CA	NIH
596 1860 1.2 ISSUED		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 DE	045394-DE	NIH
969234 1.7.8		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	06/26/2007 (12/26/2007)	P030 EP	0-15394-EP	NIH
1113517.5		6/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Response to Office Action	1/17/2007	P030 EP- DV	045394-EP DIV	NIH
2103565.7		8/16/2002	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	Tax payment	6/26/2008	P030 HK	045394-1HK	NLH
9-505834		06/26/1996	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	SEQUENCE LISTING WAS DUE 11/10/2006		P030 JP- DV	045394-JP-DIV	NIH
2006-3 868 1		2/15/2006	GENERATION OF IMMUNE RESPONSES TO PROSTATE-SPECIFIC ANTIGEN (PSA)	WAITING FOR RESPONSE FROM JPO - RESPONSETOOA WAS FILED FEBRUARY 2006		P030 JP	045394-JP	NIH
10/197,127		07/17/2002	RECOMBINANT FOX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to non-final Office Action	02/02/2007	P01 1 US	046570-CPA2C- US	NIH

2003266471	11/27/2003		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV-2	046570-AU-DIV 2	NIH
3726897 ISSUED	07/15/1997		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU	046570-AU	NIH
5419401	07/04/2001		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 AU-DV	046570-AU-DIV	NIH
2,261,989	07/15/1997		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 CA	046570-CA	NIH
97934427	07/15/1997		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/15/2007 (01/15/2008)	P011 EP	046570-EP	NIH
30884498	7/15/1997		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Response to Office Action	01/03/2007 (04/03/2007, if request is made by 01/03/2007)	P011 JP	046570-JP	NIH
10/057,136 ISSUED 7, 118,738	1/25/2002		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	4 <sup>th</sup> year Maintenance Fee	04/12/2010 (10/12/2010) EXPIRES 08/03/2019	P027 US	047113-US	NIH
6186098	02/24/1998		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax payment	02/24/2007 (08/24/2007)	P027 AU	047113-AU	NIH
2,282,300	02/24/1998		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Response to Office Action Tax payment 1	01/17/2007 02/24/2007 (02/24/2008)	P027 CA	047113-CA	NIH
98906706.1	02/24/1998		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1 TUMOR-ASSOCIATED ANTIGEN	Tax Payment	2/24/007 (08/24/2007)	P027 EP	047113-EP	NIH
10/660,369	09/11/2003		TRANSFUSED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO	Response to non-final OA TRANSFERRED TO E&A ON 11/02/2006	12/20/2006	P037 US STA (NFC)	054440-US	NIH, STANFORD
08238,611. ISSUED 5,656,465	05/04/1994 08/12/1997		METHODS OF IN VIVO GENE DELIVERY	INSTRUCTIONS TO PREPARE AN AMENDMENT BY 12/20 CONVEYED TO AND CONFIRMED BY E&A ON 12/04/2006	02/12/2009 (08/12/2009) EXPIRES 08/12/2014	RJ REF, S02-036		
2543795	05/03/1995		METHODS OF IN VIVO GENE DELIVERY	12 <sup>th</sup> year Maintenance Fee	02/12/2009 (08/12/2009) EXPIRES 08/12/2014	P024 US	042777-US	NIH
				Tax payment	05/03/2007 (11/03/2007)	P024 AU	042777-AU	NIH



2,189,452	05/03/1995	METHODS OF IN-VIVO GENE DELIVERY	Tax payment		P024 CA	042777-CA	NIH
959197443	05/03/1995	METHODS OF IN VIVO GENE DELIVERY	Tax payment		P024 EP	042777-EP	NIH
08270,106 ISSUED 5,698,530	7/1/1994	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	12 <sup>th</sup> year Maintenance Fee		P002 US	045773- US	NIH
2006092	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment		P002 AU	046773-AU	NIH
2,102,623	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment		P002 CA	046773 CA	NIH
9291353.0 ISSUED UK SE MLMC CHLU DE DK FIES FR GR IT BE AT	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment		P002 EP	046773-EP	NIH
4-512025	05/06/1992	RECOMBINANT VIRUS EXPRESSING CARCINOEMBRYONIC ANTIGEN AND METHODS OF USE THEREOF	Tax payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST		P002 J P	046773- JP	NIH
10,543,944	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Waiting for 1 <sup>st</sup> OA		P003 US	053622- US	NIH
2004291024	02/20/2004	NOVEL INSERTION SITES EN FOX VECTORS	Tax Payment and Request for Examination		P003 AU	053623-AU	NIH
2,515,890	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment Request for Examination		P003 CA	053624-CA	NIH
4,817,690	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment		P003 EP	053626-EP	NIH
2006-532394	02/20/2004	NOVEL INSERTION SITES IN FOX VECTORS	Tax Payment TRANSFERRED TO E&A ON 11/02/2006 PER NIH REQUEST		P003 J P	053627-JP	NIH
10,579,007	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Waiting for 1 <sup>st</sup> OA		P005 US	053666- US	NIH
2004289340	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment (05/12/2010)		P005 AU	5366	NIH
4810831	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Tax Payment		P005 EP	053666 3-EP	NIH
2,545,164	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Assignment due		P005 CA	053666 4-CA	NIH
2006-538904	11/12/2004	SYSTEM FOR TREATING AND PREVENTING BREAST CANCER	Request for Examination		P005 J P	053666 5-JP	NIH
10/578,025	11/12/2004	CUSTOM VECTORS FOR TREATING AND PREVENTING PANCREATIC CANCER	Waiting for 1 <sup>st</sup> OA		P004 US	053676- US	NIH

## Exhibit G

## PATENT

Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-673 1

### ASSIGNMENT

**WHEREAS**, Therion Biologics Corp. of 222 Third Street, Suite 2300, Cambridge, Massachusetts, 02142 USA (hereinafter referred to as Assignor), co-owns certain inventions for which patent applications were executed for patents, as identified in the Attachment hereto, and

**WHEREAS**, the Government of the United States of America (hereinafter referred to as Assignee) is desirous of acquiring the Assignor's right, title, and interest in and under the inventions described in the patent applications identified in the Attachment hereto,

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor assigns and transfers to the Assignee, represented by the Secretary, Department of Health and Human Services, the full and exclusive rights, title, and interest in and to (a) the patents, patent applications, and inventions identified in the Attachment hereto, whether filed in the United States or elsewhere (e.g., in any region or country of the world), (b) other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, PCT applications, national phase applications, petty patent applications, and utility model applications) that may be filed in the United States or elsewhere (e.g., in any region or country of the world) on the inventions identified in the Attachment hereto and/or that claim priority to any of the patents and patent applications identified in the Attachment hereto, and (c) the patents, extensions, or derivations thereof that may issue on or from any of the aforementioned patents and patent applications.

**ASSIGNOR HEREBY AUTHORIZES** and requests the Commissioner of Patents to issue U.S. patents to the above-mentioned Assignee agreeably with the terms of this assignment document.

**ASSIGNOR ALSO HEREBY AUTHORIZES** the Assignee to insert into this assignment document (e.g., into the Attachment hereto) the filing date and application number of any patent application identified in the Attachment hereto for which the filing date and particulars (e.g., patent number and/or patent application number) are unavailable at the time this assignment document is executed.

**UPON SAID CONSIDERATION**, Assignor conveys to the Assignee the right to make application in its own behalf for protection of the invention in the U.S. and elsewhere (i.e., in any countries) and to claim under the Patent Cooperation Treaty, the International Convention, and/or other international arrangement for any such patent application the date of the U.S. application (or any other patent application on the invention) to gain priority with respect to other patent applications.

**ASSIGNOR DOES HEREBY COVENANT** and agree with the Assignee that it will not execute any writing or do any act whatsoever conflicting with the terms of this assignment document set forth herein, and that Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee and subject to the terms of this Settlement Agreement, execute such

additional assignments and other writings as may be necessary to perfect the Assignee's enjoyment of this assignment, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representatives of all parties hereto.

IN WITNESS WHEREOF, the undersigned has set his hand on the date shown below,

Date 2/27/07

Michael S. Wyand  
Signature of Authorized Officer  
Therion Biologics Corp.

Michael S. Wyand  
Printed Name of Authorized Officer  
Therion Biologics Corp.

President + CEO  
Title of Authorized Officer  
Therion Biologics Corp.

STATE OF MA  
COUNTY OF Middlesex


On this 27 day of Feb, 2007, before me, a Notary Public in and for said county, appeared \_\_\_\_\_, whose name is \_\_\_\_\_, who is personally known to me to be the same person subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

PK Matthews  
Notary Public

My commission  
Expires: June 16, 2011

{SEAL}

100159939\_1.DOC



THERON CASE LIST-SOLELY OWNED - UNDER REVIEW							
Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref No.	IP Matter No.	I.I.C./CO-OWNED
07/092,036		Recombinant pos virus for immunization against tumor-associated antigens				P012US	
07/579,269		Virus expressing oncogene, CEA				P012USCNI	
Issued Patent 6,699,475		Virus expressing oncogene, CEA				P012USCNDV1	
PCT/US88/03032		Virus expressing oncogene, CEA				P012PCT	
1,341,435 Canada		Virus expressing oncogene, CEA				P012CA	
92913153 EP		Virus expressing oncogene, CEA				P012EP	
E248924		Virus expressing oncogene, CEA				P012AT	
92913153		Virus expressing oncogene, CEA				P012BE	
92913153		Virus expressing oncogene, CEA				P012DK	
92913153		Virus expressing oncogene, CEA				P012FR	
92913153		Virus expressing oncogene, CEA				P012GB	
20030404983		Virus expressing oncogene, CEA				P012GR	
92913153		Virus expressing oncogene, CEA				P012DE	
92913153		Virus expressing oncogene, CEA				P012IT	
92913153		Virus expressing oncogene, CEA				P012NL	
92913153		Virus expressing oncogene, CEA				P012ES	
92913153		Virus expressing oncogene, CEA				P012SE	
92913153		Virus expressing oncogene, CEA				P012CH	
92913153		Virus expressing oncogene, CEA				P012LU	
Issued US Patent 5,093,238		Recombinant Fowlpox Virus with insertions in BamHI				P015US	
07/398,762		Recombinant Fowlpox Virus with insertions in BamHI				P015USCP	
07/980,682		Recombinant Fowlpox Virus with insertions in BamHI				P015USGFCN	
PCT/US89/03701		Recombinant Fowlpox Virus with insertions in BamHI				P015PCT	
431072 EP		Recombinant Fowlpox Virus with insertions in BamHI				P015EP/GB	
1,341,234 CA		Recombinant Fowlpox Virus with insertions in BamHI				P015CA	
07/205,195		Method of Selecting for Poxvirus Recombinants				P018US	
PCT/US89/02486		Method of Selecting for Poxvirus Recombinants				P018PCT	
422072 EP		Method of Selecting for Poxvirus Recombinants				P018EP	
422072		Method of Selecting for Poxvirus Recombinants				P018GB	

506906/89		Method of Selecting for Poxvirus Recombinants					P018JP	
07340,052		Recombinant Virus by Homologous Recombination					P025US	
07510,125		Recombinant Virus by Homologous Recombination					P025USCP1	
07526,248		Recombinant Virus by Homologous Recombination					P025USCP2	
07/929,698		Recombinant Virus by Homologous Recombination					P025USCPN1	
07/926,811		Recombinant Virus by Homologous Recombination					P025USCPN2	
5,691,170		Recombinant Virus by Homologous Recombination					P025USCPNFWC	
469089		Recombinant Virus by Homologous Recombination					P025EP	
2,054,379		Recombinant Virus by Homologous Recombination					P02SCA	
469089		Recombinant Virus by Homologous Recombination					P025BE	
469089		Recombinant Virus by Homologous Recombination					P025GB	
469089		Recombinant Virus by Homologous Recombination					P025FR	
69031735.2,08		Recombinant Virus by Homologous Recombination					P025DE	
469089		Recombinant Virus by Homologous Recombination					P02SCH	
6,165,460		Poxvirus encoding PSA and use as a vaccine					P030US	
09/693,121		Poxvirus encoding PSA and use as a vaccine					P030USCN	
PCT/US96/10837		Poxvirus encoding PSA and use as a vaccine					P030PCT	
2,226,436		Poxvirus encoding PSA and use as a vaccine					P030CA	
840791		Poxvirus encoding PSA and use as a vaccine					P030EP	
1113517,5		Poxvirus encoding PSA and use as a vaccine					P030EPDV1	
840791		Poxvirus encoding PSA and use as a vaccine					P030DE	
840791		Poxvirus encoding PSA and use as a vaccine					P030FR	
840791		Poxvirus encoding PSA and use as a vaccine					P030PT	
840791		Poxvirus encoding PSA and use as a vaccine					P030GR	
840791		Poxvirus encoding PSA and use as a vaccine					P030MC	
840791		Poxvirus encoding PSA and use as a vaccine					P030IU	
840791		Poxvirus encoding PSA and use as a vaccine					P030IE	
840791		Poxvirus encoding PSA and use as a vaccine					P030FI	
840791		Poxvirus encoding PSA and use as a vaccine					P030DK	

840791		Poxvirus encoding FSA and use as a vaccine							P030IT
9-505834		Poxvirus encoding FSA and use as a vaccine							P030IP
60/449,720		Recombinant poxvirus for modulating angiogenesis							P031USPr
PCT/US04/05376		Methods for delivering angiogenic modulators using pox viruses							P031PCT
60/625,321		Methods for preparing cells and viruses							Fish & Richardson
PCT/US05/040170		Methods for preparing cells and viruses							Fish & Richardson
60/678,329		Methods and compositions for detecting immune responses							Fish & Richardson
PCT/US06/17765		Methods and compositions for detecting immune responses							Fish & Richardson
08/481,804 ISSUED 6,699,475	06/07/1995 03/02/2004	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	4th year Maintenance Fee	09/02/2007 (03/03/2008) EXPIRES 03/02/2021					04073 6-4.1 S MIT
577,071	09/02/1988	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/29/2007 (07/29/2008)					04073 6-CA MIT
89 907 535.2	06/07/1989	METHOD OF SELECTING FOR RECOMBINANT POX VIRUSES	Tax payment	06/07/2007 (12/07/2007)			F018GB		04073 7-GB
07/205,189	06/10/1998						F018US		04073 7-US
1,341,234	8/25/1989	RECOMBINANT FOWLPOX VIRUS	Tax payment	05/15/2007 (05/15/2008)			F012CA		04073 8-CA
89 910 518.3 ISSUED	08/25/1989	RECOMBINANT FOWLPOX VIRUS	Tax payment	08/25/2007 (02/25/2008)			F012EP		04073 8-EP
89 910 518.3 ISSUED	08/25/1 989	RECOMBINANT FOWLPOX VIRUS	Tax payment	08/25/2007 (02/25/2008)			F012GB		04073 8-GB
07/237,285 5,091,258	08/26/1998 03/03/1992	RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION VECTOR	All fees paid	EXPIRES 03/03/2009					04075 0-US and all foreign counterparts including 04075 6-CA, 6-BE, 6-CH, 6-DE, 6-FR, 6-GB, and 7-US.

Exhibit H



POWER OF ATTORNEY

BE IT KNOWN, that Therion Biologics Corp. of 222 Third Street, Suite 2300, Cambridge, Massachusetts, 02142 USA (hereinafter referred to as Therion), has made and appointed, and by these presents does make and appoint, Dr. Mark Rohrbaugh, Director, NIH Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 or any designee, acting on behalf of the United States Department of Health & Human Services, true and lawful attorney for Therion and, in Therion's name, place, and stead, gives and grants to said attorney, general and full authority to do and perform each and every act and thing whatsoever requisite necessary to be done with respect to (a) the patents, patent applications, and inventions identified in the Attachment hereto, whether filed in the United States or elsewhere (e.g., in any region or country of the world), (b) other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, PCT applications, national phase applications, petty patent applications, and utility model applications) that may be filed in the United States or elsewhere (e.g., in any region or country of the world) on the inventions identified in the Attachment hereto and/or that claim priority to any of the patents and patent applications identified in the Attachment hereto, and (c) the patents, extensions, or derivations thereof that may issue on or from any of the aforementioned patents and patent applications, as could be done by Therion, with full power of substitution and revocation, and hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, the undersigned has set his hand on the date shown below.

Date 2/27/07

Michael S. Wyand  
Signature of Authorized Officer  
Therion Biologics Corp.

Michael S. Wyand  
Printed Name of Authorized Officer  
Therion Biologics Corp.

President + CEO  
Title of Authorized Officer  
Therion Biologics Corp.

STATE OF MA )  
COUNTY OF Middlesex )

On this 27 day of Feb, 2007, before me, a Notary Public in and for said county, appeared \_\_\_\_\_, who is personally known to me to be the same person whose name is subscribed to the foregoing assignment document, and acknowledged that he/she signed and delivered the document as his/her free and voluntary act for the uses and purposes therein set forth.

{SEAL}

PREMA K MATTHEWS

Notary Public **PREMA K MATTHEWS**  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires June 16, 2011

My Commission Expires: \_\_\_\_\_



**PREMA K MATTHEWS**  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires June 16, 2011

THERION CASE LIST-SOLELY OWNED - UNDER REVIEW							
Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref. No.	IP Matter No.	I.I.C./CO-OWNED
07/092,036		Recombinant pos virus for immunization against tumor-associated antigens				P012US	
07/579,269		Virus expressing oncogene, CEA				P012USCN1	
Issued Patent 6,699,475		Virus expressing oncogene, CEA				P012USCNDV1	
PCT/US88/03032		Virus expressing oncogene, CEA				P012PCT	
1,341,435 Canada		Virus expressing oncogene, CEA				P012CA	
92913153 EP		Virus expressing oncogene, CEA				P012EP	
E248924		Virus expressing oncogene, CEA				P012AT	
92913153		Virus expressing oncogene, CEA				P012BE	
92913153		Virus expressing oncogene, CEA				P012DK	
92913153		Virus expressing oncogene, CEA				P012FR	
20030404983		Virus expressing oncogene, CEA				P012GB	
92913153		Virus expressing oncogene, CEA				P012GR	
92913153		Virus expressing oncogene, CEA				P012DE	
92913153		Virus expressing oncogene, CEA				P012IT	
92913153		Virus expressing oncogene, CEA				P012NL	
92913153		Virus expressing oncogene, CEA				P012ES	
92913153		Virus expressing oncogene, CEA				P012SE	
92913153		Virus expressing oncogene, CEA				P012CH	
92913153		Virus expressing oncogene, CEA				P012IU	
Issued US Patent 5,093,238		Recombinant Fowlpox Virus with insertions in BamHI				P015US	
07/398,762		Recombinant Fowlpox Virus with insertions in BamHI				P015USCP	
07/980,682		Recombinant Fowlpox Virus with insertions in BamHI				P015USPCN	
PCT/US89/03701		Recombinant Fowlpox Virus with insertions in BamHI				P015PCT	
431072 EP		Recombinant Fowlpox Virus with insertions in BamHI				P015EP/GB	
1,341,234 CA		Recombinant Fowlpox Virus with insertions in BamHI				P015CA	
07/205,195		Method of Selecting for Poxvirus Recombinants				P018US	
PCT/US89/02486		Method of Selecting for Poxvirus Recombinants				P018PCT	
422072 EP		Method of Selecting for Poxvirus Recombinants				P018EP	
422072		Method of Selecting for Poxvirus Recombinants				P018GB	

50690689		Method of Selecting for Poxvirus Recombinants						P0181P	
07/340,052		Recombinant Virus by Homologous Recombination						P025US	
07/510,125		Recombinant Virus by Homologous Recombination						P025USCP1	
07/526,248		Recombinant Virus by Homologous Recombination						P025USCP2	
07/929,698		Recombinant Virus by Homologous Recombination						P025USGFCN1	
07/926,811		Recombinant Virus by Homologous Recombination						P025USGFCN2	
5,691,170		Recombinant Virus by Homologous Recombination						P025USGFCNFWC	
469089		Recombinant Virus by Homologous Recombination						P025EP	
2,054,379		Recombinant Virus by Homologous Recombination						P025CA	
469089		Recombinant Virus by Homologous Recombination						P025BE	
469089		Recombinant Virus by Homologous Recombination						P025GB	
469089		Recombinant Virus by Homologous Recombination						P025FR	
69031735-2-08		Recombinant Virus by Homologous Recombination						P025DE	
469089		Recombinant Virus by Homologous Recombination						P025CH	
6,165,460		Poxvirus encoding PSA and use as a vaccine						P030US	
09/693,121		Poxvirus encoding PSA and use as a vaccine						P030USCN	
PCT/US96/10837		Poxvirus encoding PSA and use as a vaccine						P030PCT	
2,226,436		Poxvirus encoding PSA and use as a vaccine						P030CA	
840791		Poxvirus encoding PSA and use as a vaccine						P030EP	
11133175		Poxvirus encoding PSA and use as a vaccine						P030EPDV1	
840791		Poxvirus encoding PSA and use as a vaccine						P030DE	
840791		Poxvirus encoding PSA and use as a vaccine						P030FR	
840791		Poxvirus encoding PSA and use as a vaccine						P030PT	
840791		Poxvirus encoding PSA and use as a vaccine						P030GR	
840791		Poxvirus encoding PSA and use as a vaccine						P030MC	
840791		Poxvirus encoding PSA and use as a vaccine						P030IJ	
840791		Poxvirus encoding PSA and use as a vaccine						P030IE	
840791		Poxvirus encoding PSA and use as a vaccine						P030FI	
840791		Poxvirus encoding PSA and use as a vaccine						P030DK	

840791		Poxvirus encoding PSA and use as a vaccine							P030IT	
9-505834		Poxvirus encoding PSA and use as a vaccine							P030JP	
60/449,720		Recombinant poxvirus for modulating angiogenesis							P031USPr	
PCT/US04/05376		Methods for delivering angiogenic modulators using pox viruses							P031PCT	
60/625,321		Methods for preparing cells and viruses							Fish & Richardson	
PCT/US05/040170		Methods for preparing cells and viruses							Fish & Richardson	
60/678,329		Methods and compositions for detecting immune responses							Fish & Richardson	
PCT/US06/17765		Methods and compositions for detecting immune responses							Fish & Richardson	
08/481,804 ISSUED 6,699,475	06/07/1995 03/02/2004	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS		4th year Maintenance Fee	09/02/2007 (03/03/2008) EXPIRES 03/02/2021				04073 6-4.1 S	MIT
577,071	09/02/1988	RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS		Tax payment	07/29/2007 (07/29/2008)				04073 6-CA	MIT
89 907 535.2	06/07/1989	METHOD OF SELECTING FOR RECOMBINANT POX VIRUSES		Tax payment	06/07/2007 (12/07/2007)			P018GB	04073 7-GB	
07/205,189	06/10/1998							P018US	04073 7-US	
1,341,234	8/25/1989	RECOMBINANT FOWLPOX VIRUS		Tax payment	05/15/2007 (05/15/2008)			P012CA	04073 8-CA	
89 910 518.3 ISSUED	08/25/1989	RECOMBINANT FOWLPOX VIRUS		Tax payment	08/25/2007 (02/25/2008)			P012EP	04073 8-EP	
89 910 518.3 ISSUED	08/25/1 989	RECOMBINANT FOWLPOX VIRUS		Tax payment	08/25/2007 (02/25/2008)			P012GB	04073 8-GB	
07/237,285 5,093,258	08/26/1998 03/03/1992	RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION VECTOR		All fees paid	EXPIRES 03/03/2009				04075 0-US and all foreign counterparts including 04075 6-CA, 6-BE, 6-CH, 6-DE, 6-FR, 6-GB, and 7-US	

Exhibit I



**THERION**  
BIOLOGICS

Ronald I. Eisenstein  
NIXON PEABODY LLP  
100 Summer Street  
Boston, MA 02110

February 16, 2007

Re: Transfer of Patent Files for National Institutes of Health (See Attachment)

Mr. Eisenstein,

Pursuant to the signed Power of Attorney and as instructed herewith, please transfer all files for the referenced cases in the Attachment to the following:


John Kilyk, Jr.  
Attorney at Law  
Leydig, Voit & Mayer, Ltd.  
Two Prudential Plaza - Suite 4900  
180 North Stetson Avenue  
Chicago, IL 60601-6731

Additionally, please file a Request to Withdraw as Attorney of Record in connection with the attached matters, changing the correspondence address to the above Leydig, Voit & Mayer, Ltd. address. Lastly, instruct all of your foreign associates to correspond directly with John Kilyk, Jr.

Please acknowledge safe transfer of the files by signing below and returning a copy of this letter to the following:

Michelle A. Booden, Ph.D.  
Office of Technology Transfer  
Cancer Branch  
National Institutes of Health  
6011 Executive Blvd., Rm 325  
Rockville, MD 20852

Very truly yours,



Michael Wyand, DVM, Ph.D.  
President and CEO  
Therion Biologics, Inc.

Therion  
Biologics  
Corporation

76 Rogers Street  
Cambridge, MA  
02142

Phone (617) 475-7500  
Fax (617) 475-7501  
www.therionbio.com

Exhibit 11 of 4

THERION CASE LIST-SOLELY OWNED- UNDER REVIEW							
Application Serial No	Filing Date	Title	Next Action	Final Due Date	Client Ref. No.	IN Matter No.	I.I.C./CO-OWNED
07092,036		Recombinant pos virus for immunization against tumor-associated antigens				P012US	
07579,269		Virus expressing oncogene, CEA				P012USCN1	
Issued Patent 6,699,475		Virus expressing oncogene, CEA				P012USCNDV1	
PCT/US88/03032		Virus expressing oncogene, CEA				P012PCT	
1,341,433 Canada		Virus expressing oncogene, CEA				P012CA	
92913153 EP		Virus expressing oncogene, CEA				P012EP	
E248974		Virus expressing oncogene, CEA				P012AT	
92913153		Virus expressing oncogene, CEA				P012BE	
92913153		Virus expressing oncogene, CEA				P012DK	
92913153		Virus expressing oncogene, CEA				P012ER	
92913153		Virus expressing oncogene, CEA				P012GB	
20030404983		Virus expressing oncogene, CEA				P012GR	
92913153		Virus expressing oncogene, CEA				P012DE	
92913153		Virus expressing oncogene, CEA				P012IT	
92913153		Virus expressing oncogene, CEA				P012NL	
92913153		Virus expressing oncogene, CEA				P012ES	
92913153		Virus expressing oncogene, CEA				P012SE	
92913153		Virus expressing oncogene, CEA				P012CH	
92913153		Virus expressing oncogene, CEA				P012LU	
Issued US Patent 5,093,258		Recombinant Fowlpox Virus with insertions in BamHI				P015US	
07398,762		Recombinant Fowlpox Virus with insertions in BamHI				P015USCP	
07980,682		Recombinant Fowlpox Virus with insertions in BamHI				P015USCFCN	
PCT/US89/03701		Recombinant Fowlpox Virus with insertions in BamHI				P015PCT	
431072 EP		Recombinant Fowlpox Virus with insertions in BamHI				P015EP/GB	
1,341,234 CA		Recombinant Fowlpox Virus with insertions in BamHI				P015CA	
07205,195		Method of Selecting for Poxvirus Recombinants				P018US	
PCT/US89/02486		Method of Selecting for Poxvirus Recombinants				P018PCT	
422072 EP		Method of Selecting for Poxvirus Recombinants				P018EP	
422072		Method of Selecting for Poxvirus Recombinants				P018GB	



50690689		Method of Selecting for Poxvirus Recombinants				P0181P	
07340,052		Recombinant Virus by Homologous Recombination				P025US	
07510,125		Recombinant Virus by Homologous Recombination				P025USCP1	
07526,248		Recombinant Virus by Homologous Recombination				P025USCP2	
07929,698		Recombinant Virus by Homologous Recombination				P025USCFCN1	
07926,811		Recombinant Virus by Homologous Recombination				P025USCFCN2	
5,691,170		Recombinant Virus by Homologous Recombination				P025USCFCNFWC	
469089		Recombinant Virus by Homologous Recombination				P025EP	
2,054,379		Recombinant Virus by Homologous Recombination				P025CA	
469089		Recombinant Virus by Homologous Recombination				P025BE	
469089		Recombinant Virus by Homologous Recombination				P025GB	
469089		Recombinant Virus by Homologous Recombination				P025FR	
690317352-08		Recombinant Virus by Homologous Recombination				P025DE	
469089		Recombinant Virus by Homologous Recombination				P025CH	
6,165,460		Poxvirus encoding PSA and use as a vaccine				P030US	
09/693,121		Poxvirus encoding PSA and use as a vaccine				P030USCN	
PCT/US96/10837		Poxvirus encoding PSA and use as a vaccine				P030PCT	
2,226,436		Poxvirus encoding PSA and use as a vaccine				P030CA	
840791		Poxvirus encoding PSA and use as a vaccine				P030EP	
1113517-5		Poxvirus encoding PSA and use as a vaccine				P030EPPV1	
840791		Poxvirus encoding PSA and use as a vaccine				P030DE	
840791		Poxvirus encoding PSA and use as a vaccine				P030FR	
840791		Poxvirus encoding PSA and use as a vaccine				P030PT	
840791		Poxvirus encoding PSA and use as a vaccine				P030GR	
840791		Poxvirus encoding PSA and use as a vaccine				P030MC	
840791		Poxvirus encoding PSA and use as a vaccine				P030LU	
840791		Poxvirus encoding PSA and use as a vaccine				P030HE	
840791		Poxvirus encoding PSA and use as a vaccine				P030FI	
840791		Poxvirus encoding PSA and use as a vaccine				P030DK	

840791			Poxvirus encoding PSA and use as a vaccine						P030IT
9-505834			Poxvirus encoding PSA and use as a vaccine						P030IP
60/449,720			Recombinant poxvirus for modulating angiogenesis						P03IUSPr
PCT/US04/03376			Methods for delivering angiogenic modulators using pox viruses						P031PCT
60/625,321			Methods for preparing cells and viruses						Fish & Richardson
PCT/US05/040170			Methods for preparing cells and viruses						Fish & Richardson
60/678,329			Methods and compositions for detecting immune responses						Fish & Richardson
PCT/US06/17765			Methods and compositions for detecting immune responses						Fish & Richardson
08/481,804 ISSUED 6,699,475	06/07/1995 03/02/2004		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	4th year Maintenance Fee	09/02/2007 (03/03/2008) EXPIRES 03/02/2021				04073 6-4.1 S MIT
577,071	08/02/1988		RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST TUMOR-ASSOCIATED ANTIGENS	Tax payment	07/29/2007 (07/29/2008)				04073 6-CA MIT
89 907 535.2	06/07/1989		METHOD OF SELECTING FOR RECOMBINANT POX VIRUSES	Tax payment	06/07/2007 (12/07/2007)			P018GB	04073 7-GB
07/205,189	06/10/1998							P018US	04073 7-US
1,341,234	8/25/1989		RECOMBINANT FOWLPOX VIRUS	Tax payment	05/15/2007 (05/15/2008)			P012CA	04073 8-CA
89 910 518.3 ISSUED	08/25/1989		RECOMBINANT FOWLPOX VIRUS	Tax payment	08/25/2007 (02/25/2008)			P012EP	04073 8-EP
89 910 518.3 ISSUED	08/25/1989		RECOMBINANT FOWLPOX VIRUS	Tax payment	08/25/2007 (02/25/2008)			P012GB	04073 8-GB
07237,285 5,093,258 ISSUED	08/26/1998 03/03/1992		RECOMBINANT FOWLPOX VIRUS AND RECOMBINATION VECTOR	All fees paid	EXPIRES 03/03/2009				04075 0-US and all foreign counterparts including 04075 6-CA, 6-BE, 6-CH, 6-DE, 6-FR, 6-GB, and 7-US